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Summary 
 
Hepatitis C virus belongs to the family of Flaviviridae and contains a single stranded 
RNA genome in positive orientation. The genome carries a single polyprotein open 
reading frame (ORF), which is flanked by two highly structured RNA stretches, the 5’- 
and 3’-untranslated regions (UTRs). In these UTRs several secondary structures 
were identified to be necessary for HCV translation and replication.  
The internal ribosome entry site (IRES), which is required for translation, comprises 
three of the four stem loops present in the 5’-UTR. In addition two microRNA-122 
(miR-122) binding sites are located upstream of the IRES. The 3’-UTR comprises a 
variable region (VR), a poly U/C tract and three conserved stem loops. In the VR an 
additional miR-122 binding site was identified. miR-122 was shown to stimulate HCV 
translation and replication possibly by protecting the HCV RNA from degradation.  
This work focused on the question whether miR-122 recruits a microRNA-protein 
complex to its binding sites on the HCV RNA and which components this complex 
contains. Towards this end an anti-Argonaute (Ago) protein-specific – HCV RNA co-
immunoprecipitation was developed. Using this method it could be shown that two of 
the four members of the Ago protein family, Ago1 and Ago2, are recruited to the HCV 
RNA in a miR-122 dependent manner. For the miR-122 binding site in the VR of the 
3’-UTR it has also been shown that Ago2 can be recruited by miR-122. This however 
is only the case when four nucleotides located in a stem loop in the NS5B coding 
region are present. These findings give rise to the assumption that for this miR-122 
binding site not only the seed sequence but also four additional nucleotides located 
close to the 3’-end of the miR-122 bind to the HCV RNA.  
Finally, employing a time course assay it has been shown that miR-122 prolongs the 
half-life of a wild type HCV reporter RNA compared to a mutant that is not able to 
bind miR-122 or compared to the wild type in presence of a control miR-122. This 
experiment also shows that, besides stabilizing the HCV RNA, miR-122 seems to 
directly stimulate HCV translation.  
Thus, it seems that miR-122 recruits a microRNA-protein complex and positively 
influences the HCV life cycle via two different mechanisms. Firstly, miR-122 
enhances HCV RNA stability, most likely by protecting it from degradation. Secondly, 
miR-122 improves HCV translation efficiency probably by changing the IRES 
structure to a conformation favorable for translation.  
Zusammenfassung 
 
 
Zusammenfassung 
 
Das Hepatitis C Virus (HCV) gehört zu der Familie der Flaviviridae und besitzt ein 
einzelsträngiges RNA-Genom in (+)-Strang-Orientierung. Dieses Genom enthält 
einen einzelnen offen Leserahmen für das Polyprotein. Dieser ist von 5‘- und 3‘-nicht 
translatierten Regionen (UTRs) flankiert, in welchen sich viele Sekundärstrukturen 
befinden, die unerlässlich für die Translation und Replikation des Virus sind.  
Die sogenannte „internal ribosome entry site“ (IRES) in der 5‘-UTR besteht aus drei 
Haarnadelstrukturen und ist unerlässlich für die Translationsinitiation des HCV ist. 
Zusätzlich besitzt die 5‘-UTR zwei microRNA-122 (miR-122) Bindestellen 
stromaufwärts der IRES. Die 3‘-UTR umfasst eine variable Region (VR), einen poly-
U/C-Trakt sowie drei konservierte stem loops. Auch hier befindet sich, im Bereich der 
VR, eine miR-122 Bindungsstelle. Des Weiteren wurde für miR-122 nachgewiesen, 
dass sie stimulierend auf die Translation und Replikation wirkt, möglicherweise indem 
sie die HCV-RNA vor Abbau schützt.  
Das Hauptaugenmerk der vorliegenden Arbeit lag auf der Frage, ob miR-122 einen 
microRNA-Proteinkomplex (miRNP) an die HCV-RNA rekrutiert und welches die 
Proteinkomponenten dieses Komplexes sind. Zur Untersuchung dieser Fragestellung 
wurde eine Argonaute (Ago) Protein spezifische – HCV-RNA Koimmunpräzipitation 
entwickelt. Mit dieser Methode konnte nachgewiesen werden, dass zwei der vier 
Mitglieder der Ago-Proteinfamilie, Ago1 und Ago2, durch miR-122 an die HCV-RNA 
rekrutiert werden. Bezüglich der miR-122 Bindestelle in der VR der 3‘-UTR konnte 
gezeigt werden, dass abhängig von miR-122 Ago2 auch hier binden kann allerdings 
nur, wenn neben der bekannten miR-122 Bindesequenz auch vier Nukleotide der 
NS5B-kodierenden Region vorhanden sind. Folglich ist, nicht nur die seed-Sequenz 
der miR-122 notwendig für die effiziente Bindung an die HCV 3‘-UTR, sondern auch 
vier Nukleotide am 3‘-Terminus von miR-122. 
Zusätzlich wurde ein Zeitverlaufsversuch durchgeführt, um die Stabilität der HCV-
RNA zu testen. Dabei wies ein HCV-Reporter-RNA eine höhere Halbwertszeit in 
Anwesenheit von miR-122 auf als ein vergleichbare Mutante, die miR-122 nicht 
binden kann, oder der Wildtyp in Anwesenheit einer Kontroll-miR. Zusätzlich scheint 
miR-122 neben der Stabilisierung der HCV-RNA auch einen direkten positiven Effekt 
auf die HCV Translation zu haben. 
Zusammengefasst rekrutiert miR-122 einen miRNP-Komplex an die HCV-RNA und 
beeinflusst den Lebenszyklus des HCV positiv durch zwei unterschiedliche 
Mechanismen. Zum einen erhöht miR-122 die Stabilität der HCV-RNA, 
möglicherweise durch die Verhinderung des Abbaus der HCV-RNA. Zum anderen 
verstärkt miR-122 die HCV-Translationseffizienz, möglicherweise dadurch, dass die 
Bindung von miR-122 die Struktur der IRES beeinflusst und diese in eine 
Konformation bringt die vorteilhaft für die Translation ist. 
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1 Introduction 
 
1.1 Hepatitis C Virus Infection  
The Hepatitis C virus (HCV) was first cloned by Choo and coworkers in 1989 and 
was identified as the causative agent of the NonA-NonB hepatitis (Choo et al, 1989). 
According to the World Health Organization (WHO) about 150 million people 
worldwide are chronically infected with HCV causing more than 350.000 deaths per 
year (WHO, 2012).  
Two to six weeks after infection only about 20 % of the infected people develop 
symptoms, which range from fever, fatigue, nausea, abdominal and joint pain to 
jaundice.  
However, in most cases the infection takes a subacute development which increases 
the risk of chronic infections. It is estimated that about 55 - 85 % of all patients get 
chronically infected with this liver tropic virus and have a probable chance of 20 % for 
developing liver cirrhosis which increases the risk for hepatic cancer (Hoofnagle, 
2002; Jeong et al, 2012; Seeff, 2002). 
Transmission of HCV occurs mainly via blood and blood products as well as with 
organ transplants. Contaminated medical equipment, like reused syringes and 
needles, is also a source of infection, which especially poses a threat to drug addicts 
and patients in countries with poor medical standards. 
As a treatment a combination of nucleoside analogues (ribavirin) and polyethylene 
glycol (PEG)-bound-interferon-α is usually used after diagnosis. In some cases, 
recently approved inhibitors targeting the NS3-4A protease of HCV are also added to 
the drug cocktail (Pawlotsky, 2013). Until today no vaccination against HCV is 
available. 
1.2 Classification of HCV  
HCV belongs to the family of Flaviviridae (Simmonds et al, 1993) which is comprised 
of the genera Flavivirus, Pestivirus, Pegivirus (Stapleton et al, 2011) and Hepacivirus. 
The genus Hepacivirus contains only two members, HCV and the recently discovered 
GBV-B (Muerhoff et al, 1995; Simons, 1995). Well-known members of the Flavivirus 
family are the yellow fever virus, from which the family name is derived (lat. flavus, 
yellow), the Dengue fever virus and West Nile virus.  
Following the Baltimore classification (Baltimore, 1971) the Flaviviridae were 
categorized in group IV which indicates that the viruses comprising this group contain 
a single stranded RNA genome in (+)strand orientation. Hepatitis C virus is 
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subdivided into seven genotypes which are genetically divergent from each other. 
These genotypes also show a varying distribution across the world, with the subtypes 
1a and 1b being the most predominant in Europe (Zein, 2000).  
1.3 Hepatitis C Virus  
1.3.1 Structure of HCV 
Under the electron microscope HCV particles are pleomorphic and have diameters 
between 30 and 80 nm (Bradley et al, 1985; He et al, 1987; Yuasa et al, 1991). HCV 
virons contain an approximately 9.6 kilobases (kb) long single-stranded RNA genome 
with positive polarity. The genome is packed into an icosahedral capsid formed by 
the viral Core protein. A viral envelope surrounds the capsid and is composed of a 
lipid bilayer derived from the cellular membrane of the host cell. Two viral 
glycoproteins E1 and E2 are embedded in the lipid envelope. The viral particle can 
associate with low-density lipoproteins (Andre et al, 2002; Miyamoto et al, 1992; 
Nielsen et al, 2006; Thomssen et al, 1992) which are thought to facilitate attachment 
to the host cell (Bankwitz et al, 2010; Dreux et al, 2006; Prentoe et al, 2011).  
 
Figure 1: Structure of the HCV particle.The 
viral particle is made up of the host cell-
derived lipid membrane with the embedded 
viral glycoproteins E1 and E2, and the capsid 
containing the single stranded RNA genome. 
The viral particle is associated with a 
lipoprotein particle. Modified from 
Bartenschlager et al., 2004 (Bartenschlager et 
al, 2004). 
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1.3.2 Genome and polyprotein  
 
 
Figure 2: Structure and translation products of the HCV genome. Shown is the 
approximately 9.6 kb long HCV genome with secondary structures in the 5’- and 3’- UTR. 
Upon IRES-dependent translation the polyprotein is synthesized and subsequently cleaved 
into ten sub-proteins. Arrows show autoprotease cleavage by NS2 and NS3, closed 
diamonds indicate cleavage by the edoplasmatic reticulum signal peptidase while open 
diamonds indicate cleavage by signal peptide peptidase. The structural proteins shown in the 
ORF of the genome comprise the core, E1 and E2 protein. Nonstructural proteins are all 
proteins from p7 to NS5B. Modified from Moradpour et al.,2007 (Moradpour et al, 2007). 
 
 
The viral genome is approximately 9.6 kb in length and can be roughly divided into 
three parts; the 5’- untranslated region (5’-UTR), the single open reading frame 
(ORF) coding for the viral polyprotein and the 3’-UTR.  
The 5’-UTR contains four stem loops. Stem loop I and parts of stem loop II were 
shown to be important for genome replication (Friebe et al, 2001). Stem loop II, III 
and IV form the viral internal ribosome entry site (IRES) which is used to initiate 
translation directly at the translation start site (Brown et al, 1992; Tsukiyama-Kohara 
et al, 1992; Wang et al, 1993). Stem loop IV partly reaches into the core coding 
region of the polyprotein ORF.  
The 3’-UTR contains a variable region (VR), a poly(U/C) tract and the stem loops 1, 2 
and 3. It is assumed that the poly(U/C) tract serves as a binding site for the viral 
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helicase non-structural protein (NS) 3 (Kim et al, 1995; Suzich et al, 1993) and the 
phosphoprotein NS5A, which was shown to regulate viral replication (Gwack et al, 
1996; Huang et al, 2005; Lohmann et al, 1997).  
The ORF codes for a single large polyprotein that is post-translationally cleaved, 
partly autoproteolytically and partly by cellular proteases, to produce ten sub-
proteins, the structural proteins Core, E1 and E2 and the non-structural proteins p7, 
NS2, NS3, NS4A, NS4B, NS5A and NS5B. The RNA secondary structures essential 
for the viral translation and replication, as well as the cleavage events of the 
polyprotein and the known functions of the ten sub-proteins (Lohmann, 2013; 
Moradpour & Penin, 2013; Niepmann, 2013) are illustrated in Figure 2. 
In addition the HCV RNA contains several conserved binding sites for the liver 
specific microRNA-122 (miR-122), two of which are located in the 5’-UTR upstream 
of the IRES and one is situated in the variable region of the 3’-UTR. It has been 
shown that miR-122 enhances HCV replication and translation and evidence is 
emerging that miR-122 protects the HCV RNA from degradation (Henke et al, 2008; 
Jopling et al, 2005; Shimakami et al, 2012a; Shimakami et al, 2012b; Wilson et al, 
2011). In addition there were primate studies suggesting that miR-122 might be a 
promising target for anti-viral treatment to improve the prospect for chronically 
infected patients (Lanford et al, 2010). 
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1.3.3 Replication cycle 
 
 
 
Figure 3: Replication cycle of HCV. HCV recognizes several surface proteins of the host 
cell using them as receptors to be endocytosed into the cell. Upon acidification of the 
endosome, the viral RNA is released into the cytoplasm. Subsequently, the IRES-dependent 
translation and processing of the polyprotein takes place. The genome is then replicated and 
the newly synthesized genomes are packed into new viral particles and released from the 
cell. Modified from Ploss and Rice,2009 (Ploss & Rice, 2009). 
 
 
In the blood stream HCV is associated with lipoprotein particles forming a lipo-viro 
particle. This association is assumed to facilitate attachment to the host cell via 
several cellular receptor molecules necessary for cholesterol transport such as 
SR-BI, LDLR and NOC1L1. A subset of receptors that may be utilized by HCV to 
enter the host cell has been identified, including OCLN, CLDN1 and CD81 (Ploss et 
al, 2009; Zeisel et al, 2013). It has been shown that the viral glycoprotein E2 interacts 
with SR-BI, CD81 and glycosaminoglycans (GAG). 
The virus is internalized via clathrine-dependent endocytosis. When the inside of the 
endophagosome is acidified, it induces fusion of the viral envelope with the 
endosomal membrane at a pH range of 6.3 - ~4.0 (Pietschmann et al, 2009; 
Tscherne et al, 2006). It seems that CD81 and CLDN1 together with E1 and E2 play 
a major role in these events. It is assumed that the acidification of the endosome 
  Introduction 
6 
triggers a conformational change in the two viral glycoproteins which in-turn initiates 
fusion, analogous to other viral fusion events (Bressanelli et al, 2004; Modis et al, 
2004). After fusion the viral RNA is released into the cytoplasm. 
The viral RNA is subsequently translated into protein by IRES mediate translation, 
which occurs at the endoplasmic reticulum (ER). After cleavage of the polyprotein, all 
non-structural proteins remain associated with the ER membrane. Next, NS4B 
induces the formation of invaginations in the ER membrane (Welsch et al, 2009). 
Together these membrane alterations form the so called membranous web (Egger et 
al, 2002) and are the sites of viral genome replication (Gosert et al, 2003). Key 
enzyme in the synthesis of new genomes is the RNA-dependent RNA polymerase 
NS5B. This enzyme catalyzes the formation of (+)strand genome copies that are 
used as a template by NS5B for production of a new generation of HCV genomes 
(Behrens et al, 1996; Lohmann et al, 1997).  
Assembly and release of viral particles from the host cell is still not well understood. It 
has been shown that lipid droplets (Barba et al, 1997; Boulant et al, 2006; 
McLauchlan et al, 2002; Moradpour et al, 1996) and the endosomal-sorting complex 
required for transport (ESCRT) pathway (Ariumi et al, 2011b; Corless et al, 2010; 
Tamai et al, 2012) play a major role in storage and trafficking of viral components and 
infectious particles but the mechanism stays unclear. Newly formed particles bud into 
the ER (Gastaminza et al, 2008) and pass through the Golgi before they are released 
(Vieyres et al, 2010). How and when the viral particle is associated with the 
lipoprotein particles is unclear, but it has been shown that nascent viral particles are 
complexed with apolipoprotein ApoE (Coller et al, 2012) indicating that the 
association occurs during virus assembly.  
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1.4 Cap-dependent translation versus IRES mediated translation 
initiation 
Like some other positive strand RNA viruses HCV initiates the translation of its 
genome by employing an internal ribosome entry site (IRES) instead of using a Cap-
structure. This IRES is mainly located in the 5’-UTR, spanning from stem loop II to 
stem loop IV and also comprising a small part of the Core coding region of the 
polyprotein ORF. 
The act of initiating translation at an IRES element differs significantly from the 
initiation at a Cap structure commonly used in cellular mRNAs and will be discussed 
in more detail below. 
 
 
Figure 4: Schematic depiction of the Cap- and HCV IRES-mediated translation 
initiation. (A) Sequence of the binding events of eukaryotic initiation factors (eIFs) to mRNA 
in case of Cap-dependent translation initiation. Firstly, the eIF4 subunits bind the Cap 
structure on the mRNA. Secondly, the preformed 43S pre-initiation complex is recruited. 
Subsequently, a scanning process for the translation start codon (AUG) occurs. When the 
AUG is found, the eIFs leave the complex and the 60S large ribosomal subunit is recruited. 
(B) Sequence of binding events in case of translation initiation at the HCV IRES. The 40S 
small ribosomal subunit binds directly to the tRNA-like stem loop IV. Afterwards, eIF3 and 
eIF2 in complex with the methionine carrying starter tRNA are recruited. After eIF5 promoted 
hydrolysis of the GTP which is part of the eIF2-initiator tRNA complex, the 60S ribosomal 
subunit is recruited and translation can commence. Modified from Fraser and Doudna, 2007 
(Fraser & Doudna, 2007). 
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1.4.1 Cap-dependent translation initiation 
A Cap-structure is comprised of a 7-methyl guanosine bound to the RNA via a 5’-5’ 
tri-phosphate bond. In the event of translation initiation, first the eukaryotic initiation 
factor (eIF) 4F complex comprised of its subunits A, E, G and the accessory factors B 
and H is recruited to the Cap, whereas eIF4E is the subunit which is directly 
interacting with the Cap (Gingras et al, 1999; Jackson et al, 2010). eIF4A possesses 
a helicase activity which is used to smooth out secondary structures of the mRNA, 
supported by its co-factors eIF4B and H (Marintchev et al, 2009; Rogers et al, 1999). 
The 43S pre-initiation complex, containing the small ribosomal subunit and the eIFs 
1, 2 and 3, is subsequently recruited by eIF4G (Gingras et al, 1999; LeFebvre et al, 
2006). eIF2 is associated with the Methionine carrying initiator tRNA (tRNAiMet). 
Following the binding, a scanning process occurs in search for the translation start 
codon AUG (Pestova & Kolupaeva, 2002). When the start codon is found eIF1 leaves 
the complex and eIF5 induces hydrolysis of the GTP bound by eIF2 in the ternary 
complex. The eIFs are released and the 60S large ribosomal subunit binds, forming 
the 80S ribosome (Paulin et al, 2001; Unbehaun et al, 2004). Figure 4 A shows the 
events taking place at the Cap.  
 
1.4.2 IRES-mediated translation initiation  
IRESs are classified by their need of eukaryotic initiation factors for translation 
initiation. Classically, there are four groups of IRES-structures, class I comprising 
Entero- and Rhinoviruses, class II of Cardio- and Aphthoviruses, class III containing 
the Hepatitis A virus, and class IV which HCV was assigned to (Figure 5).  
In contrast to the Cap-dependent initiation, the IRES-mediated initiation of HCV 
translation (Figure 4 B) follows a distinctly different mechanism. Only three of the 
canonical translation initiation factors, eIF3, eIF2 and eIF5, are used.  
Stem loop IV possesses a pseudo knot structure that resembles a tRNA, also 
including the translation start codon, AUG. The small ribosomal subunit is directly 
recruited to this structure. After binding of the small ribosomal subunit stem loop IV 
unfolds, positioning the AUG with adjacent sequences in the mRNA binding cleft 
(Berry et al, 2011). In the following eIF3 binds to stem loop III contacting the 40S 
subunit (Jackson et al, 2010). eIF3 is not needed for the recruitment of the 40S 
subunit to the IRES but it facilitates the binding and stabilizes the formation of the 
80S complex (Fraser & Doudna, 2007). Subsequently, the ternary complex 
comprised of eIF2, the tRNAiMet initiator tRNA and GTP binds. It has been shown that 
under certain circumstances like cellular stress eIF2 can be substituted by other 
factors like eIF5B (Terenin et al, 2008), eIF2D (Dmitriev et al, 2010) or eIF2A (Kim et 
al, 2011) and thus eIF2 is not absolutely required for translation initiation at the IRES. 
  Introduction 
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eIF5 helps in the recognition of the start codon by the ternary complex and stimulates 
GTP hydrolysis (Pestova et al, 1998). Finally, the 60S subunit binds releasing the 
eIFs except for eIF3 which seems to stay associated with the ribosome (Weinlich et 
al, 2009). 
For Cap-dependent translation it is known that the circularization of the mRNA, 
accomplished by an interaction of eIF4A with the Poly(A) binding protein (PABP), 
enhances translation efficiency. The proposed mechanism implies that the 
circularization leads to a more stable binding of the eIF4F complex to the mRNA 
enhancing the speed of translation (re)-initiation. In case of HCV it has been shown 
that the 3’-end also enhances the translation efficiency (Bung et al, 2010; Song et al, 
2006). It is hypothesized that the circularization of the HCV RNA might also play a 
role in translation efficiency, but the involved proteins and the mechanism by which it 
might be accomplished remain unknown. For cellular mRNAs and the HCV RNA both 
this circularization might be used as a system to ensure the integrity of the RNA, so 
that only undegraded (i.e. functional) RNAs get efficiently translated.  
 
 
Figure 5: The four groups of classical IRES structures. Shown are the four classical 
groups of IRES-structures. IRESs are classified according to their needs of canonical 
initiation factors to initiate translation. Class I shows the IRES of the Entero- and Rhino 
viruses, class II the IREs of the Cario- and Aphtoviruses, class II the IRES of Hepatitis A 
virus and class IV shows the IRES of HCV, as a member of the Flaviviridae that carries an 
IRES. The stem loops are shown by either roman (class I, II and IV) or arabic (class II) 
numbers. py signifies a poly-pyrimidine tract. miR shows the two binding sites of miR-122 in 
the HCV 5’-UTR. Modified from Niepmann, 2009 (Niepmann, 2009). 
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1.4.3 IRES trans-acting factors 
Besides the canonical eIFs, IRES-dependent translation is known to use IRES 
transacting factors (ITAFs) to augment translation efficiency. In case of HCV several 
proteins have been identified that bind to parts of the IRES and influence translation. 
ITAFs identified for HCV include the La protein, NSAP1, hnRNP L, hnRNP D, IMP-1, 
Gemin5, LSm1-7 and PCBP2. Figure 6 gives an overview of these proteins showing 
their structural features and their influence on HCV translation. Most of these proteins 
contain several RNA interaction domains which enable them to bind to the HCV RNA, 
like the RNA recognition motif (RRM), the KH domain (Makeyev & Liebhaber, 2002) 
and the La motif domain (Martino et al). It has been shown that several of these 
proteins can interact with each other, like La protein with LSm1-7 (Maraia & 
Lamichhane, 2011) or NSAP1 with IMP-1.  
Additionally other factors have been identified that are assumed to stimulate HCV 
translation but are not counted to the ITAFs such as microRNA-122 and the 
Argonaute proteins (Henke et al, 2008; Wilson et al, 2011). 
 
 
Figure 6: HCV IRES trans-acting factors. Shown are the different IRES transacting factors 
of the HCV IRES, with domains that are important for RNA interaction (dark grey) like the 
RNA recognition motif (RRM), the KH domain or the La protein domain. The effect on HCV 
translation is shown on the right side (+ meaning stimulation; – meaning reduction). Picture 
taken from Niepmann, 2013 (Niepmann, 2013). 
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1.5 microRNAs 
1.5.1 microRNA biogenesis and function 
 
Figure 7: Biogenesis and processing of 
cellular microRNAs (miRs). miRs are 
transcribed in the nucleus by RNA 
polymerase II into primary-microRNA (pri-
miR). This pri-miR is then processed down 
by the endonuclease Drosha/DGRC8, 
creating a hairpin containing precursor-
miR. The pre-miR is subsequently 
exported into the cytoplasm by 
Exportin5/Ran-GTP and further cleaved 
by Dicer. This leads to the creation of a 
miR duplex, which is unwound by the 
Argonaute (Ago) proteins. The guide 
strand is kept in complex with Ago as part 
of the RNA-induced silencing complex 
(RISC) and used as a template to identify 
target mRNAs which, dependent on the 
matching of the guide strand, are either 
degraded or translationally repressed. 
Modified from Filipowitz et al., 2008 
(Filipowicz et al, 2008) 
 
 
 
 
 
 
 
 
 
 
 
microRNAs (miR) are 21-25 nucleotides long RNA molecules, which are transcribed 
in the nucleus by RNA Polymerase II as capped and polyadenylated primary (pri)-
microRNAs. These pri-miRs are encoded either by protein coding intron sequences 
or by non-coding RNA exons and introns (Rodriguez et al, 2004; Saini et al, 2007). 
After transcription they are recognized by the microprocessor complex comprised of 
the RNase III endonuclease Drosha and the double strand RNA binding protein 
DGRC8, which cleaves them into a 70 nts long precursor miR (pre-miR) containing a 
hairpin structure, a 5’ phosphate and a 3’ two nucleotides overhang (Gregory et al, 
2004). The pre-miR is transported into the cytoplasm by Exportin 5/Ran-GTP where it 
undergoes an additional cleavage by Dicer, leading to a double stranded about 22 
nts long miR duplex containing a guide-strand and a passenger strand as well as 
two-nucleotides overhangs at the 3’-ends of both strands (Kim et al, 2009; Lund et al, 
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2004). Dicer can form a complex with TRBP a double-stranded RNA binding protein 
which also interacts with Ago proteins. Whereas TRBP is not required for pre-miR 
cleavage by Dicer it was shown to be necessary for the loading of the miR duplex to 
the Ago-proteins (Castanotto et al, 2007; Chendrimada et al, 2005; Haase et al, 
2005). Dicer, TRBP and Ago2 form the minimal requirement for the RISC complex 
but it has also been shown that the interaction of other proteins like PACT is 
important for efficient RNA interference (Lee et al, 2006).  
During the unwinding of the duplex miR, the guide strand stays in complex with Ago 
while the passenger strand is degraded. The decision which strand becomes the 
passenger and which the guide depends on the thermodynamical stability at the ends 
of the duplex miR. The strand with its 5’-end residing at the less stable end of the 
duplex becomes the guide (Khvorova et al, 2003; Rand et al, 2005; Schwarz et al, 
2003). 
 
 
 
Figure 8: Argonaute protein structure. (A) Schematic depiction of the domains contained 
in Ago proteins. In red the common Asp-Asp-His motif of Ago proteins with ‘slicer’ activity is 
shown. (B) Structure of a Ago protein bound to miR (red) and target mRNA (blue). The PAZ 
(purple) and Mid (orange) domains interact with the 5’- and 3’-end of the miR, respectively. 
The PIWI domain interacts with the miR-mRNA duplex. Taken from Czech and Hannon, 
2011 (Czech & Hannon). 
 
The Ago protein family contains four members in humans Ago1 to 4, of which only 
Ago2 has endonuclease (called ‘slicer’) activity. The miR interacts with three domains 
in the Ago protein called PAZ, Mid and PIWI. The 3’-end of the miR resides in the Mid 
domain whereas the 5’-phosphate residue of the miR interacts with the PAZ domain. 
Figure 8 shows the structure of an Ago protein complexed with miR and target mRNA 
(Czech & Hannon, 2011) 
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It is well established that miRs take part in the post-translational repression of gene 
expression by hybridizing to mRNA and inhibiting their translation. To accomplish this 
miRs usually bind with their seed sequence to complementary sites in the 3’-UTR of 
the target mRNA. The seed sequence spans nucleotide 2 to 8 at the 5’-end of the 
miR, determining the miRs target range. The binding of the seed region does not 
have to be perfect and bulges in areas where nucleotides are not able to hybridize 
are common, broadening the possible spectrum of target mRNAs for the miR (Orom 
& Lund, 2010). 
Depending on the matching of the miR seed sequence to the miR binding site and 
the proteins involved, the translational repression of the mRNA may follow different 
mechanisms. A perfect matching seed sequence leads to cleavage and subsequent 
degradation of the mRNA. In humans this process occurs only with the involvement 
of Ago2 since it is the only human Argonaute protein that carries a ‘slicer’ activity, 
enabling it to cleave the target strand. This ‘slicer’ activity is harbored in the PIWI 
domain of the Ago protein and often shows an Asp-Asp-His motif (Czech & Hannon, 
2011). In contrast, formation of bulges during the binding of the miR leads to 
sequestration of the mRNA in so called processing-bodies (P-bodies) (Liu et al, 
2005). P-bodies are sites in the cytoplasm of cells for storing not needed mRNAs that 
are either eventually released when the need arises or are degraded. The biogenesis 
of miRs is summarized in Figure 7. 
In addition to translational repression of mRNAs miRs have been shown to stimulate 
translation of a target RNA (Henke et al, 2008; Orom et al, 2008; Vasudevan et al, 
2007) by a yet unknown mechanism. 
 
1.5.2 Function of miR-122  
The single locus for miR-122 lies on chromosome 18 and is part of an exon of the 
non-coding hcr RNA (Chang et al, 2004). miR-122 is highly liver-specific where it 
represents more than 70 % of the total miR population (Lagos-Quintana et al, 2001) 
with about 66000 copies per cell in an adult liver (Chang et al, 2004). 
It has been shown that miR-122 plays a role in the regulation of cholesterol 
biosynthesis (Esau et al, 2006; Krutzfeldt et al, 2005) as well as iron homeostasis by 
influencing the expression of hemochromatosis and hemojuvelin (Castoldi et al, 
2011).  
Furthermore, data suggests that in hepatocellular carcinoma (HCC) miR-122 levels 
are typically low (Kutay et al, 2006) which in most cases predicts a bad outcome for 
the patient (Coulouarn et al, 2009). It has been shown that in cancerous liver cells 
overexpression of miR-122 may have a tumor-suppressing effect (Bai et al, 2009). 
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1.5.3 Effect of miR-122 and Ago proteins on HCV  
The effect of miR-122 on the HCV lifecycle caused a lot of controversy in the last 
couple of years. In 2005 Jopling and coworkers reported a direct interaction of 
miR-122 with the HCV 5’-UTR in the region of two predicted miR-122 binding sites 
located upstream of the HCV IRES. They observed that sequestration of endogenous 
miR-122 in cells transfected with a HCV-specific replicon RNA resulted in a reduction 
of HCV RNA abundance compared to cells where miR-122 was present. During the 
course of their experiments the authors could neither attribute this effect to HCV 
translation stimulation nor to the stabilization of the HCV RNA so they assumed that 
the increase in RNA abundance was due to a stimulation of RNA replication (Jopling 
et al, 2005). 
These findings were questioned when Henke, Goergen et al. published a study in 
which they showed that HCV translation was positively influenced by miR-122. Their 
results also gave rise to the assumption that miR-122 might have more than one 
effect on the HCV RNA since the stimulating effect of miR-122 that they observed 
was more pronounced when using replication competent HCV RNA rather than the 
replication deficient RNA (Henke et al, 2008).  
In the context of virus production it has been shown that a direct interaction of 
miR-122 with the HCV genome is necessary to gain infectious virus and that binding 
site 1, the one closer to stem loop I in the HCV 5’-UTR, seems to be more important 
in this context than site 2 (Jangra et al, 2010). The authors of this study also claimed 
that the stimulation of translation is a rather moderate effect of miR-122 and 
proposed a possible stabilization of the HCV genome or stimulation of RNA synthesis 
as the main effect of miR-122 binding to the HCV RNA. 
The idea of stabilization of the HCV RNA was supported later by Shimakami et al. 
who have showed that the half-life of replication deficient HCV RNA is strongly 
increased in the presence of miR-122. They further showed that a non-translationally 
effective artificial Cap-structure at the HCV 5’-UTR mimics the role of miR-122, and 
that it protects the HCV RNA from degradation (Shimakami et al, 2012a).  
Experiments on the miR-122-HCV RNA complex formation revealed that the binding 
of miR-122 to the two 5’ binding sites is unusual. It seems that not only does the seed 
sequence of miR-122 bind to its respective counterparts on the HCV RNA, but also 
several nucleotides 3’ of the miR-122 seed sequence hybridize to sequence 
elements upstream of the binding sites. In this context especially the nucleotides 15 
and 16 of miR-122 seem to be crucial for the accumulation and stabilization of HCV 
RNA (Machlin et al, 2011; Shimakami et al, 2012b). 
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This mode of binding of miR-122 to the HCV RNA leads to the formation of a bulge 
and a tail region in the miR (Figure 9). Furthermore, the tail region is thought to play 
an important role in miR-122-dependent up-regulation of HCV RNA translation and 
accumulation (Machlin et al, 2011; Roberts et al, 2011).  
 
Figure 9: miR-122 forms an 
unusual RNA complex with the 
HCV 5’-UTR. Shown is the 
proposed binding behavior of 
miR-122 (green) to the HCV 5’-
UTR (black). miR-122 binds not 
only with its seed sequence to 
the binding sites (ACACUCC / 
CACUCC) but also forms an 
interaction with three or four 
nucleotides 3’ of the seed 
sequence, forming a bulge and 
tail region. Modified from Machlin 
et al., 2011 (Machlin et al, 2011). 
 
Recent studies revealed that the Ago proteins also have a stimulatory effect on HCV 
translation, RNA accumulation and virus production which seem to be linked to the 
action of miR-122 on the HCV RNA (Machlin et al, 2011; Randall et al, 2007; Roberts 
et al, 2011; Wilson et al, 2011). It is hypothesized that Ago delivers miR-122 to the 
HCV RNA as part of a miRNP effector complex. In fact, another recent study 
published in 2012 by Shimakami and coworkers, showed a direct interaction of Ago2 
and to a lesser degree Ago1 with the HCV RNA in a miR-122-dependent manner 
(Shimakami et al, 2012a). The involvement of other components of RISC in the 
action of miR-122 and the Ago proteins on HCV remains unclear. 
  
  Introduction 
16 
1.6 Aims of the Work  
It is well established that Ago proteins have a positive effect on HCV replication 
(Machlin et al, 2011; Randall et al, 2007; Roberts et al, 2011; Wilson et al, 2011). 
Thus it was hypothesized that this effect of Ago is linked to the stimulation of HCV 
RNA accumulation and translation displayed by miR-122. The main goal of this body 
of work was to investigate whether Ago proteins directly interact with the 5’-UTR of 
the HCV RNA and if this binding would be miR-122 dependent, by using an Ago 
protein-specific co-IP assay. Furthermore, this method was used to explore if the 
highly conserved miR-122 binding site in the variable region of the HCV 3’-UTR is 
accessible for miR-122-dependent Ago binding. 
In addition, the role of spacing between miR-122 binding sites in the 5’-UTR and the 
IRES as well as the function of the two miR-122 binding sites was addressed. 
Sequence analysis of several HCV sub-types showed that the distance between the 
miR-122 binding sites in the 5’-UTR and the IRES is highly conserved. It was 
assumed that miR-122 recruits a microribonucleoprotein (miRNP) complex the miR-
122 binding sites in the HCV 5’-UTR, which is able to interact with the translation 
initiation machinery bound by the IRES and thus stimulates HCV translation. Thus, 
mutants were created that carry several nucleotides long insertions in between the 
IRES and the miR sites and it was tested whether those insertions impair translation 
stimulation by miR-122. 
Next, the individual effect of the two miR-122 sites in the 5’-UTR on the HCV RNA 
was explored. It has been shown that both replication and translation of the HCV 
RNA can be stimulated by miR-122 (Henke et al, 2008; Jopling et al, 2005). This 
gave rise to the question whether both miR sites present in the 5’-UTR contribute 
equally to these effects or if both sites perform separate tasks. To address this 
question one mutant in which both miR-122 binding sites can be addressed 
separately by using two different artificial miRs was created. 
Finally, the role of miR-122 in protection of the HCV RNA from degradation was 
explored. Therefore, a mutant in which the miR-122 sites are masked in a stem loop 
rendering it unable to interact with miR-122 was produced. This mutant was used in 
time course assays to see if its reporter activity diminishes more quickly than the 
activity of the wild type HCV RNA. The reporter activity is a direct measure of RNA 
abundance and thus was used as an indicator of RNA degradation over time.  
Results 
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2  Results  
 
2.1 Establishing an anti-Ago – HCV RNA co-immunoprecipitation 
At the beginning of this work it was known that microRNA-122 (miR-122) enhances 
the replication of HCV, but the exact mechanism accounting for this effect remained 
unclear. Jopling and coworkers claimed that miR-122 directly elevates the production 
of new genomes (Jopling et al, 2005), while results from the Niepmann group showed 
that miR-122 also stimulates HCV RNA translation (Henke et al, 2008), thereby not 
excluding additional  modes of action. The current general opinion by now is that both 
of these effects are most likely due to the protection of the HCV RNA from 
degradation by miR-122 (Jangra et al, 2010; Shimakami et al, 2012a; Shimakami et 
al, 2012b).  
The identification and characterization of cellular proteins involved in the stimulating 
effect of miR-122 is important to generate a comprehensive model of how miR-122 
enhances HCV replication. Since only double stranded miR-122 showed an effect in 
the cellular context (Goergen & Niepmann, 2012) it was assumed that a protein 
complex might be involved in the unwinding of the miR-122 duplexes and delivering 
the guide strand to the site of action. The most likely candidates to accomplish this 
task are the proteins of the Argonaute (Ago) family. The four members of this protein 
family, Ago1 to Ago4, recognize and unwind micro-RNA duplex precursors, which are 
then used to specifically target certain cellular mRNAs.  
To identify the Ago proteins associated with the HCV RNA in the presence of 
miR-122 an anti-Ago protein HCV RNA co-immunoprecipitation (co-IP) was 
established. 
 
2.1.1  Testing of the co-IP components 
Because Ago2 is the most abundant Argonaute in HeLa cell lysate, making 60 % of 
the total Ago proteins (Petri et al, 2011), it was chosen for the co-IP experiments. 
Firstly a highly specific anti-Ago2 antibody for the anti-Ago protein - HCV RNA co-IP 
was needed, preferably one that has been already used for an immunoprecipitation 
of Ago2. Thus it was decided to try the rat-anti-Ago2 antibody clone 11A9 that was 
used by Rüdel and coworkers (Rüdel et al, 2008). This antibody was tested in a 
Western Blot assay, using HeLa cell lysate (Figure 10). In the beginning non-purified 
antibody from hybridoma supernatant (kindly provided by G. Meister, Figure 10, left 
lane) was used, later the 11A9 became also available from Sigma Aldrich as a 
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purified antibody (Figure 10, right lane); the usage of either antibody is indicated. 
Results obtained from Western Blots using both of the anti-Ago2 11A9 antibodies 
show only one specific band, representing Ago2, at about 100 kDa with no detectable 
background in HeLa lysate. Thus there is no cross reaction of these antibodies with 
unrelated HeLa cell proteins. 
The reason to favor HeLa cells above the human hepatoma cell line HuH-7 is that 
HeLa cells show no detectable levels of endogenous miR-122 (Henke et al, 2008) 
that might lead to false positive results in the following co-IP assays.  
 
Figure 10: Western Blot using two different 
anti-Ago2 11A9 antibody preparations. HeLa 
cell lysate was separated on an SDS - 8 % 
polyacrylamide gel and blotted on a PVDF 
membrane. The left blot was stained using a 
rat-anti-Ago2 antibody clone 11A9 provided as 
hybridoma supernatant (dilution 1:50). The right 
blot was stained using the same anti-Ago2 
antibody provided as purified solution (dilution 
1:1000). As secondary antibody a goat-anti-rat 
antibody specific for the IgG light chain and 
coupled to peroxidase was used (dilution 
1:20000).  
 
 
 
 
 
Since the concentration of the 11A9 antibody in the hybridoma supernatant was 
unknown, a Dot Blot assay was carried out to approximate the binding capacity of the 
antibody to the magnetic beads that were to be used. It was decided to use protein G 
magnetic beads, since protein A does not bind rat IgG. Therefore 5 µl of the protein 
G magnetic beads (as provided by supplier, NEB) were rotated for 1 hour at 4 °C in 
the presence of varying amounts of hybridoma supernatant. The results indicate that 
the best ratio to obtain beads saturated with antibody is 5 µl of beads complemented 
with 15 µl of supernatant. This ratio results in a good binding of antibody to the beads 
(Figure 11, lower panel) and a low amount of unbound antibody in the supernatant 
(Figure 11, upper panel). 
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Figure 11: Titration of 11A9 antibody versus magnetic beads. 5 µl of magnetic protein G 
beads were incubated with varying amounts of rat-anti-Ago2 11A9 hybridoma supernatant. 
The beads-bound antibody and the residual antibody in the supernatant were blotted on a 
PVDF membrane and stained with a goat-anti-rat peroxidase (POD) secondary antibody 
(dilution 1:10000). 
 
The next step was to find out how efficiently the antibody binds Ago2 protein during 
an immunoprecipitation. Therefore, four 9 cm dishes of approximately 80 % confluent 
HeLa cells were lysed and pooled to a final volume of 800 µl. The pooled lysate was 
pre-cleared at 4 °C for 1 h using non-coupled protein G beads (25 µl beads per 
200 µl lysate). The pre-cleared lysate was then was divided into four samples at 
200 µl, each representing a 9 cm dish into which different amounts of fresh beads 
and anti-Ago2 11A9 antibody were added (at a constant ratio of 15 µl antibody per 5 
µl of beads). The samples were rotated for 2 h at 4 °C. The beads were subsequently 
washed and cooked for 5 minutes in SDS-sample buffer. Finally a Western Blot 
assay was performed. 
 
 
 
Figure 12: Titration of antibody coupled magnetic beads versus HeLa cell lysate. 
200 µl cell lysate obtained from one 9 cm dish of ~80 % confluent HeLa cells was rotated for 
2 hours at 4 °C with different amounts of magnetic protein G beads and rat-anti-Ago2 11A9 
hybridoma supernatant. As a negative control 200 µl beads without antibody were used. After 
washing, the beads were cooked with SDS-sample buffer and the supernatant was 
separated on an 8 % SDS-polyacrylamide gel. Finally, the gel was transferred to a PVDF 
membrane. The rat-anti-Ago2 antibody clone 11A9 provided as hybridoma supernatant was 
used as a primary antibody (dilution 1:50). The secondary antibody used for staining was a 
goat-anti-rat POD (dilution 1: 20000). 
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The results indicate that optimal pull-down of Ago2 is achieved by using 100 µl of 
antibody-coupled beads, using 200 µl of beads and antibody results only in a 
marginal increase in protein pull-down efficiency (Figure 12). 
 
Summarizing the previous results, it seems that for one 9 cm tissue culture dish with 
~80 % confluent HeLa cells one should use 100 µl of the magnetic protein G beads 
complemented with 300 µl of the rat-anti-Ago2 11A9 antibody to obtain optimal 
results.  
 
2.1.2 Anti-Ago2 - HCV RNA co-IP with following reverse transcriptase - PCR 
Having done the preliminary experiments, the next question was whether the HCV 
RNA could be pulled down along with Ago2 in a miR-122 dependent manner. 
Therefore, a co-immunoprecipitation protocol was employed using reverse 
transcriptase - RCR (RT-PCR) to detect the co-precipitated RNA.  
The two miR-122 binding sites in question are located in the 5’-UTR of the HCV RNA 
genome, upstream of the IRES element. To cover this region two primers were 
designed for RT-PCR that produce a fragment 245 nucleotides (nts) in length. The 
forward primer covers the loop of stem loop I and reaches across the first miR-122 
binding site, while the reverse primer is located slightly upstream of the 3’-end of 
stem loop III (Figure 13).  
 
 
Figure 13: Localization of RT-PCR primers in the 
HCV 5’-UTR. Shown is a schematic depiction of the 
HCV 5’-UTR and parts of the core protein coding 
region. Indicated are the relative positions of the 
two RT-PCR primers (red). Forward primer 1 (RT-
HCV pos. 9 - 29) spans from nucleotides 9 - 29, 
covering part of stem loop I and reaching into the 
first miR-122 binding site. Reverse primer 2 (RT-
HCV pos. 233 – 253) spans nucleotides 233 
through 253 and thus covers parts of stem loop III. 
The expected fragment produced by these primers 
is 245 nts in length.  
 
 
 
 
 
For the co-IP HCV-SIN RNA was in vitro transcribed using a double stranded DNA 
template generated by PCR from the pHCV-SIN plasmid. The HCV-SIN RNA 
comprised a small in-frame linker sequence of 96 nts consisting of the part of the 
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Core coding sequence necessary for IRES formation and the 5’-part of the firefly 
luciferase open reading frame, flanked by the HCV 5’- and 3’-UTR. 
 
 
 
Figure 14: Results of two different co-IP experiments with subsequent RT-PCR. HeLa 
cells were transfected with HCV-SIN RNA together with either miR-122 or miR-124. After 4 h 
the cells were lysed and used in an anti-Ago2 immunoprecipitation for 2 h, using anti-Ago2 
11A9 antibodies from supernatant coupled to magnetic protein G beads. The beads were 
washed and the co-precipitated RNA was released from the proteins and used in an RT-
PCR. Given are two different experiments using two different RNA release and cleanup 
protocols.  
 
The in vitro transcription was carried out at 37 °C in the presence of T7 RNA 
polymerase. HeLa cells, seeded on 9 cm-dishes, were subsequently transfected with 
HCV-SIN RNA and lysed after 4 h. Following the immunoprecipitation protocol 
described before the lysates were pre-cleared with native beads. After pre-clearing 
beads and anti-Ago2 11A9 hybridoma supernatant were added and the samples 
were rotated at 4 °C for 2 h. The Ago2-bound RNA was then extracted from the 
beads and purified following the specifications of the Qiagen RNeasy RNA clean-up 
Kit using a buffer containing guanidine thiocyanate and β-mercaptoethanol. The 
cleaned RNAs were then used in a RT-PCR assay and the products were then 
separated on an agarose gel and stained with ethidium bromide.  
Unfortunately, the results obtained with this method were not convincing (Figure 
14 A). The sample in which no microRNA was present shows a strong band, both 
samples with miR-122 or miR-124, respectively, show very faint bands. If Ago2 would 
bind miR-122 independently all samples should show the same outcome. Thus it was 
assumed that the bands were unspecific background. To make sure that those 
artifacts were not due to varying RNA recovery from the column-based RNA clean-up 
it was decided to use the phenolic peqGOLD TriFastTM solution from peqlab to 
detach the RNAs from Ago2. In the following, the RNA was precipitated with 
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Isopropanol. However, this approach was also found to be insufficient to avoid 
unspecific background (Figure 14 B).  
 
2.1.3 Attempts to improve RT-PCR detection of HCV RNA 
Since the previous experiments showed high amounts of unspecific products it was 
decided to check if this background might stem from DNA contamination in the 
samples that might have been introduced during the experimental procedure. To 
ensure the exact length of the 3’-end of the transfected RNA a DNA template was 
created by PCR from the plasmid pHCV-SIN and used for in vitro transcription. Both 
the template and the plasmid are possible sources of contamination during RT-PCR. 
The exact way of how this DNA might be carried into the samples is not clear, either 
it was residual DNA from the in vitro transcription that was still mixed with the RNA or 
it could also be possible that the used co-IP buffers contained traces of the pHCV-
SIN plasmid. To detect and remove both possible contaminations a DNase I digest 
as well as a DNA test PCR were introduced into the work flow. The primers for the 
test PCR were the same as the ones used for template production and thus should 
be able to detect both, the DNA template and the plasmid (Figure 15). 
 
 
Figure 15: Primer positions for the DNA contamination control PCR in pHCV-SIN. 
Shown are the relative positions of the two primers (red arrows) in the pHCV- SIN plasmid. 
Primer 1 (HCMV-4986 for) reaches from nucleotide 2935 – 2961, primer 2 (3X rev) covers 
the nucleotides 637 – 658. The arrows indicate the direction of the primers. Together both 
primers produce a fragment of 959 nts which is equivalent to the DNA template for the in 
vitro RNA synthesis. 
 
Applying these changes, samples were treated with DNase I for 1 h after release and 
isopropanol precipitation of the RNA. Subsequent purification was carried out 
following the TriFast protocol. These steps were repeated at least twice before the 
samples were tested for DNA contamination. If this test for the presence of DNA was 
positive, the procedure of DNase digest and clean-up was repeated until PCR 
showed no DNA background, and only then the samples were used in RT-PCR. The 
last row of Figure 16 gives an example of a test PCR without DNA background. The 
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implementation of these changes in the protocol at first had promising results (Figure 
16 C), showing a single band only in the sample containing miR-122. Unfortunately, 
these results were not reproducible (Figure 16 D).  
 
 
 
Figure 16: Results of different co-IP experiments with subsequent DNA test PCR and 
RT-PCR. HeLa cells were transfected with HCV-SIN RNA together with either miR-122 or 
miR-124. After 4 h the cells were lysed and used in an anti-Ago2 immunoprecipitation for 2 h, 
using anti-Ago2 11A9 antibodies from supernatant coupled to magnetic protein G beads. The 
beads were washed and the co-precipitated RNA was released from the proteins and used in 
an RT-PCR. Given are four different experiments using three different RNA release and 
cleanup methods. The lowest panel gives an example of the test PCR used to detect DNA 
contaminations arising from either the pHCV-SIN plasmid or the DNA template used to 
synthesize the transfected RNA. As a positive control (CRTL) 10 ng of pHCV-SIN plasmid 
was used, the negative CRTL consisted of double distilled and autoclaved water. 
 
In total the co-IP experiments using RT-PCR as a readout system did not work out in 
these experiments. All experiments showed either high unspecific background or low 
reproducibility. Since DNA contamination does not seem to be the issue it was 
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assumed that the amount of RNA recovered after multiple DNase I digest and clean-
up rounds was too low and variable to give reliable results. To avoid the necessity for 
multiple clean-up rounds of the RNA and for PCR amplification, it was decided to 
change the readout from RT-PCR products to radioactively labeled RNA which could 
be directly analyzed on a gel after detachment from Ago2 protein.  
 
2.1.4 Anti-Ago2 - HCV RNA co-IP using radioactively labeled HCV RNA 
Since the previous co-IP experiments with subsequent RT-PCR did not provide 
convincingly reproducible results, most likely due to too low RNA recovery from the 
clean-up steps, it was decided to circumvent the necessity for extensive RNA clean-
up and amplification procedures by using radioactively labeled HCV RNA for a direct 
readout.  
As before a double stranded DNA template was amplified from the pHCV-SIN 
plasmid and used in an in vitro transcription to produce HCV-SIN RNA. During the 
transcription process the RNA was labeled using 32P-UTP.  
HCV-SIN RNA was then transfected along with either miR-122 or miR-124 into 80 % 
– 90 % confluent HeLa cells grown on a 6-well plate. 6 h post-transfection the cells 
were harvested and lysed. For the co-IP the lysate was pre-cleared and the HCV 
RNA was subsequently co-precipitated with Ago2 using 100 µl of protein G magnetic 
beads coupled with anti-Ago2 antibody from hybridoma supernatant. After washing, 
the RNA was extracted from the beads following the RNeasy clean-up protocol.  
The samples were then separated on a 10 % polyacrylamide gel in the presence of 
7 M urea and the radioactive RNA was detected by autoradiography.  
Figure 17 gives the results of two independent co-IP experiments. These 
experiments showed that sometimes there was a very small increase in band 
intensity favoring RNA recovery in the sample with miR-122 (Figure 17 A), but those 
results were also not consistently reproducible (Figure 17 B). Furthermore, for some 
of the experiments carried out following this protocol it was problematic to recover 
any RNA from the samples at all (data not shown). 
In summary, the co-IP experiments using radioactively labeled HCV RNA as readout 
did not work out as expected and failed to provide constantly reliable results. The 
detected bands were most likely the result of unspecific background binding of 
radioactive RNA to the magnetic beads. This could also possibly explain the massive 
problems encountered during the co-IP assays with consecutive RT-PCRs for 
detection. These results led to the assumption that the readout was not the most 
pressing issue in the experiments, but rather the co-IP procedure itself was flawed.   
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Figure 17: Results of two co-IP 
experiments using radioactively 
labeled HCV RNA. HeLa cells grown to 
~80 % to 90 % confluency in a 6-well 
plate were transfected with radioactively 
labeled HCV-SIN RNA along with either 
miR-122 or miR-124 or no microRNA. 
The cells were lysed and the lysate was 
used in an anti-Ago2 
immunoprecipitation. After pull-down 
the co-precipitated RNA was released 
from the proteins, cleaned and 
separated on a 10 % polyacrylamide 
gel with 7 M urea. Shown are the 
results of two experiments, following the 
same protocol.  
 
 
 
 
Concerning the experiments so far it was assumed that the amount of RNA 
recovered from the samples was much too low for reliable results. Possible factors 
influencing the recovery of RNA were either the transfection efficiency or the co-IP 
itself. Factors influencing transfection efficiency would be the amount of cells and 
RNA, as well as the transfection time. In the previous assays 6-well plates with 
approximately 80 % confluent HeLa cells were used and transfected for 4 h with 1 µg 
of radioactively labeled RNA.  
Regarding the co-IP some possible points that may need troubleshooting are the 
compositions of the lysis and washing buffers as well as the amount of washing 
steps. Furthermore, the transfection of RNA into the cells and the detachment of RNA 
from Ago2 protein might also be steps that need optimization.  
Very helpful discussions with other scientist showed that some of these points are 
really critical. A breakthrough was finally accomplished when numerous changes 
from the Ago2-co-IP protocol published by Dr. Beitzinger from Prof. Meister’s 
laboratory in Regensburg, Germany (Beitzinger & Meister, 2011), were implemented. 
Those changes concerned mostly the co-IP procedure itself by altering the lysis 
buffer, the amount of washing steps and the RNA detachment and clean-up protocol. 
All changes to the co-IP protocol are shown in detail below in Table 1. 
Finally, the RNA used was changed from HCV-SIN RNA to a much smaller fragment 
comprising only the first 386 nucleotiodes (nts) of the HCV-SIN RNA covering the 
complete HCV 5’-UTR and parts of the luciferase open reading frame (ORF). That 
way it was expected to get a more favorable RNA fragment to transfection reagent 
ratio as well as less RNA degradation during the co-IP. Later this fragment was 
further shortened by 23 nts (see Figure 19). 
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 Previous co-IP protocol  New co-IP protocol  
Cell amount 6-well plate with ~80 % HeLa 
cells 
9 cm dish with ~80 % HeLa cells 
RNA amount 1 µg radioactively labeled HCV-
SIN RNA  
3 µg radioactively labeled HCV 5’- 
UTR  
RNA size  full HCV-SIN RNA  HCV-SIN RNA fragment 
comprising the first 386 nts (later 
the first 363 nts) 
Transfection time 4 h 6 h 
Lysis buffer 20 mM Tris-HCl, pH 7.5; 150 mM 
NaCl; 0.5 % Nonidet P-40; 2 mM 
EDTA; 0.5 mM DTT, 1 mM NaF; 1 
mM Pefablock (Roche) 
25 mM Tris-HCl, pH 7.5; 150 mM 
KCl; 0.5 % Nonidet P-40; 2 mM 
EDTA; 0.5 mM DTT 
Preclearing of lysate  Yes  No 
Antibody Anti-Ago2 11A9 hybridoma 
supernatant provided by Prof. G. 
Meister 
Anti-Ago2 11A9 purified antibody 
provided by Sigma Aldrich  
coupling of Antibody to 
magnetic beads  
during co-IP; rotated for 2 h at 
4 °C 
before co-IP; rotated overnight at 
4 °C 
co-IP time 2 h  3 h 
Washing buffer 50 mM Tris-HCl, pH 7.5; 300 mM 
NaCl; 5 mM MgCl2; 0.05 % 
Nonidet P-40 
50 mM Tris-HCl, pH 7.5; 300 mM 
NaCl; 5 mM MgCl2; 0.05 % 
Nonidet P-40 
Washing steps three repetitions at room 
temperature  
at least four repetitions with 
washing buffer and one time with 
PBS at room temperature 
RNA detachment from Ago2 
and clean-up 
RNeasy RNA clean-up protocol  Proteinase K digest for 15 
minutes at 65 °C and phenol- 
chloroform extraction and ethanol 
precipitation 
 
Table 1: Changes in the co-IP protocol after unsuccessful experiments with 
subsequent RT-PCR or autoradiography.  
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2.2 Anti-Ago2-HCV RNA co-IP using a HCV 5’-UTR RNA fragment  
Applying the previously discussed changes (Table 1) to the co-IP protocol it was 
finally possible to achieve constantly reliable results.   
In short, on the first day purified anti-Ago2 11A9 from Sigma Aldrich was pre-coupled 
to magnetic beads. On the second day 3 µg of the radioactively labeled short HCV 5’-
UTR RNA fragments along with the same amount of either miR-122 or miR-124 were 
transfected for 6 h into HeLa cells, grown to approximately 80 % confluency on a 
9 cm tissue culture dish. The cells were lysed and the lysate was mixed with the pre-
coupled beads. 10 % of the lysate was saved as an input control. The co-IP was 
carried out for 3 h at 4 °C under constant rotation. Subsequently, the beads were 
washed and 10 % of the washed beads were stored for a Western Blot assay to 
detect the bound Ago2 protein. The rest of the sample and the input control were 
treated with Proteinase K, the RNA was purified by phenol-chloroform extraction and 
precipitated overnight with ethanol and sodium acetate. On the third day the 
precipitated RNA was separated on a polyacrylamide gel and exposed to an X-ray 
film.  
 
2.2.1 Anti-Ago2-RNA co-IP using HCV 5’-UTR-386 RNA 
Following the new co-IP protocol, small RNA fragments comprising the first 386 nts of 
the HCV-SIN RNA (HCV 5’-UTR-386) along with miR-122 or miR-124 were 
transfected into HeLa cells. In total four samples were produced (Figure 18 B), three 
including miR-122 and one including miR-124. After cell lysis the supernatant was 
used for co-IPs utilizing three different antibodies for the three miR-122 positive 
samples. The first sample was precipitated with an anti-eIF3a antibody. eIF3a is 
known to bind the HCV IRES microRNA independently and thus served as a positive 
control for the co-IP reaction. The second antibody targeted the FLAG epitope which 
does not naturally occur in cells. This sample served as a negative control to detect 
unspecific background. The last antibody was the anti-Ago2 11A9 antibody provided 
by Sigma Aldrich and was used for the last miR-122 sample as well as for the miR-
124 sample.  
As described before, for each sample RNA input and anti-Ago2 Western Blot controls 
were carried out to ensure an equal RNA transfection and Ago2 precipitation 
efficiency (Figure 18 A and C).  
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Figure 18: Anti-Ago2-RNA co-IP using HCV 5’-UTR-386 RNA. HeLa cells were transfected 
with radioactively labeled HCV RNA (HCV 5’-UTR-386) along with either miR-122 or miR-124 
as a negative control. 6 h post-transfection, the cells were lysed, and 10 % of the lysate was 
saved as an input control (A). The rest of the lysate was used in anti-Ago2 
immunoprecipitation. anti-eIF3a and anti-FLAG antibodies were used as positive and 
negative control. After washing 10 % of the magnetic beads used for the precipitation were 
stored for Western Blot analysis (C). The co-precipitated RNA was released from the proteins 
by Proteinase K digest, purified by chloroform - phenol extraction and precipitated with 
ethanol. The input controls were treated likewise. All RNAs were then separated on a 6 % 
Polyacrylamide gel with 7 M urea (B). Purified transcript was used as a marker for RNA 
integrity. The gel was subsequently dried and exposed to film. 
 
 
The experiment shows a miR-122 dependent recovery of the HCV RNA (lane 4) with 
no binding detectable in the sample with miR-124. The input and Western Blot control 
show no significant differences in transfection and pull down efficiency among the 
samples. The input control was problematic, obviously the resuspension of the RNA 
pellet after ethanol precipitation was not satisfactory, but it was possible to solve this 
issue in later experiments by heating the RNA to 65 °C during the resuspension 
process (see Figure 20 A).  
Based on these results it was concluded, that Ago2 binds to the HCV 5’-UTR in a 
miR-122 dependent manner. Surprisingly, during the experiments two very prominent 
bands appeared in the miR-122 sample precipitated with the anti-ago2 antibody of 
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the co-IP. One band representing the HCV RNA fragment at the same height as the 
transcript used for transfection (lane 1) and another slightly smaller. The occurrence 
of the lower band was reproducible during all the experiments even though it was 
highly variable in its intensity (data not shown). For the eIF3a sample that band was 
not detected so prominently but in this case also HCV 5’-UTRs were precipitated that 
have not yet been bound by miR-122 and Ago2. This gave rise to the question 
whether Ago2 induces cutting of the test RNA and if the cutting occurs at the 5’- or 3’-
end of the RNA. 
  
2.2.2 Anti-Ago2-RNA co-IP using HCV 5’-UTR-363 RNA 
As described in the previous chapter the experiments showed two RNA bands after 
co-IP representing the HCV 5’-UTR-386 RNA, which suggests that the RNA was 
probably cut after transfection. The question was whether this cut occurred on the 5’ 
or 3’-end of the RNA and if it was induced by the binding of Ago2 or an artifact 
coming from the method.  
Since the HCV RNA fragment used so far also included part of firefly luciferase open 
reading frame the question arose, if this was the part that was degraded during the 
co-IP procedure. It was likely that this part of the RNA was not tightly packed with 
cellular proteins like the rest of the HCV 5’-UTR and thus was more accessible for 
RNases.  
 
Figure 19: Positions of reverse primers for HCV 5’-
UTR template production. Given are the positions of 
the two reverse primers (primer 1: pHCV-FL pos 360-
386 (blue), primer 2: pHCV-FL pos 334 – 363 (red)) 
used to produce the DNA templates for the in vitro 
transcription of the HCV 5’-UTR-386 and HCV 5’-UTR-
363 RNAs. The forward primer for these DNA templates 
was HCMV-4986 for.  
 
 
 
 
 
 
To check this hypothesis a new RNA fragment, 23 nucleotides shorter than the 
HCV5’-UTR-368 RNA, was created reaching into stem loop IV of the IRES (Figure 
19). This short RNA fragment, called HCV 5’-UTR-363, was transfected into HeLa 
cells and a co-IP assay was performed as described before (Figure 20).  
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Figure 20: Anti-Ago2-RNA co-IP using HCV 5’-UTR-363 RNA. HeLa cells were transfected 
with radioactively labeled HCV RNA (HCV 5’-UTR-363) along with either miR-122 or miR-
124, as a negative control. 6 h post-transfection, the cells were lysed and 10 % of the lysate 
was saved as an input control (A). The rest of the lysate was used in anti-Ago2 
immunoprecipitation. anti-eIF3a and anti-FLAG antibodies were used as positive and 
negative control. After washing 10 % of the magnetic beads used for the precipitation were 
stored for Western Blot analysis (C). The co-precipitated RNA was released from the proteins 
by Proteinase K digest, cleaned by chloroform - phenol extraction and precipitated with 
ethanol. The input controls were treated likewise. All RNAs were then separated on a 6 % 
Polyacrylamide gel with 7 M urea (B). Purified transcript was used as a marker for RNA 
integrity. The gel was subsequently dried and exposed to X-ray film.  
 
 
Using this shorter RNA fragment only one distinct band in the miR-122 sample 
(Figure 20 lane 5) was present. This led to the conclusion that the degradation of the 
HCV 5’-UTR-386 RNA occurred at the 3’-end of the fragment. Furthermore, it was 
concluded that the observed cutting of the RNA was not due to Ago2 binding, but 
rather it was an artifact that stems from a sequence stretch in the luciferase open 
reading frame, that is not tightly associated with protein during the co-IP. 
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2.2.3 co-IP assay of the HCV 5’-UTR using an anti-Ago1 antibody  
Since miR-122 dependent binding of Ago2 to the HCV 5’-UTR was detected it was 
decided to test whether other members of the Argonaute protein family were able to 
bind to it as well. Ago1 was chosen as a new target since it is the second most 
abundant Ago protein in HeLa cell lysate, making up 22 % of the whole Ago protein 
population (Petri et al, 2011). 
 
 
 
Figure 21: Anti-Ago1-RNA co-IP using HCV 5’-UTR-386 RNA. HeLa cells were transfected 
with radioactively labeled HCV RNA (HCV 5’-UTR-383) along with either miR-122 or miR-
124, as a negative control. 6 h post-transfection, the cells were lysed and 10 % of the lysate 
was saved as an input control (A). The rest of the lysate was used in anti-Ago2 
immunoprecipitation. anti-eIF3a and anti-FLAG antibodies were used as positive and 
negative control. After washing 10 % of the magnetic beads used for the precipitation were 
stored for Western Blot analysis (C). The co-precipitated RNA was released from the proteins 
by Proteinase K digest, cleaned by chloroform - phenol extraction and precipitated with 
ethanol. The input controls were treated likewise. All RNAs were then separated on a 6 % 
Polyacrylamide gel with 7 M urea (B). Purified transcript was used as a marker for RNA 
integrity. The gel was subsequently dried and exposed to X-ray film.  
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The co-IP was performed following the same protocol as before except that now the 
rat-anti Ago1 clone 4B8 antibody was used which is commercially available from 
Sigma Aldrich (Figure 21).  
In those assays a miR-122 dependent association of Ago1 with the HCV 5’-UTR 
(lane 5) could be detected, even though the detected band appears to be much 
weaker than the one seen with Ago2. The explanation for this result might be the 
differences in Ago protein abundance as well as the quality of the two used 
antibodies. Looking at the Western Blot assay for the experiments with Ago2 and 
Ago1 it can be seen that the amount of precipitated Ago1 is much lower than the 
amount of precipitated Ago2, hinting to a significant difference in their protein binding 
affinity.  
Thus it seems that both Ago1 and Ago2 are able to bind to the HCV 5’-UTR in a miR-
122 dependent manner, but it is not possible to draw any conclusions concerning the 
stability or efficiency of that binding. 
 
2.3 Creating a HCV 5’-UTR with separately addressable microRNA 
binding sites 
The HCV 5’-UTR carries two binding sites for miR-122, one close to stem loop I, the 
other directly in front of stem loop II. Machlin and coworkers (Machlin et al, 2011) 
found evidence that not only the seed sequence of miR-122 binds to the HCV RNA 
but also three to four nucleotides further to the 3’-end of the microRNA might bind to 
the HCV RNA as well, thus upon binding the microRNA would form bulge and tail 
region. It was furthermore shown that this unconventional miR binding was necessary 
to stabilize the HCV RNA by possibly protecting it from degradation.  
Those findings raised the question whether miR-122 could perform two different 
tasks in the HCV 5’-UTR, firstly maintaining HCV RNA integrity by protecting it from 
RNases and secondly recruiting cellular factors that influence HCV translation. 
Furthermore, it would be interesting to elucidate if both sites are necessary for both 
effects or if one site conveys only one effect. 
Therefore, it was decided to mutate both miR-122 binding sites and additional binding 
areas in the HCV RNA, so that it would be possible to address them separately with 
two artificial microRNA. The sequences of the new mutated sites are given in Figure 
22.  
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Figure 22: Schematic depiction of 
the HCV m1/m2 5’-UTR. Given are 
the sequences of the wild type and 
mutated m1/m2 HCV 5’-UTR and 
their relative position. Shown in grey 
are the mutations in the miR binding 
sites that match the miR-122 seed 
sequence. Mutations in the regions, 
which presumably bind to 
nucleotides in the 3’-region of miR-
122 (Machlin et al, 2011) are 
highlighted in white. 
 
 
 
 
 
 
 
The new sequences were introduced by a two-step mutagenesis PCR, which is 
described in detail in the method section. In short, at first two PRCs were performed, 
creating two DNA fragments carrying the desired mutations in the miR-site 1 and 
miR-site 2 (Figure 23 A). Both fragments overlap partially so they can serve as a 
template for the third PCR using the two outermost primers to fill in gaps and amplify 
the mutated insert which then can be cloned into the vector backbone (Figure 23 B). 
 
 
Figure 23: Model of the two-step mutagenesis PCR to create HCV m1/m2. In the first 
step the mutations were introduced by two separate PCRs using mutagenesis primers 1 and 
2 for the first PCR and primers 3 and 4 for the second (A). The resulting DNAs from both 
PCRs partially overlap and can be used as a template for the third PCR (B) in which primers 
1 and 4 are used to fill up the gaps and amplify the mutated final fragment.  
 
 
The mutated HCVm1/m2 5’-UTR was cloned into the HCV-FL construct to replace 
the wild type HCV 5’-UTR and sequencing showed that the mutations were correctly 
introduced into the HCV sequence.  
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Before starting the final experiments, the secondary structure of HCVm1/m2 from the 
first nucleotide to the 3’-end of stem loop II was predicted. The result of this 
prediction is shown in Figure 24. Unfortunately, this test revealed a high probability 
that the mutations interfere with the natural folding of the HCV 5’-UTR, destroying 
stem loop I and II and masking the mutated miR-binding sites in newly formed stems. 
These results forced the cancellation of all experiments concerning this part of the 
project until a new clone is created and tested in silico.  
 
 
 
Figure 24: Secondary structure prediction of the wild type HCV 5’-UTR compared to 
the HCm1/m2 5-UTR. In silico model of the HCV wild type and HCV m1/m2 5’-UTRs 
including the sequence to the 3’-base of stem loop II. Given in red are the positions of the 
two miR-122 binding sites. Colors indicate base pair probabilities. The program used was 
provided online (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). The parameters applied were 
“minimum free energy and partition function”, “no dangling ends energy”, “Andronescu 
model, 2007” and “avoid isolated base pairs” at 37 °C. 
 
2.4 Anti-Ago2-HCV RNA co-IP using HCV 3’-UTR RNA fragments 
In addition to the two miR-122 binding sites in the 5’-UTR of the genome, HCV also 
carries one conserved potential binding site for miR-122 in the variable region of the 
3’-UTR. So far it could not be shown that this site has any significant effect on HCV 
translation stimulation by miR-122 (Henke et al, 2008), neither have there been any 
reports of effects on replication for this site. It was decided to test whether this highly 
conserved site is used as a target for miR-122 and Ago2 binding.   
 
2.4.1 Anti-Ago2 co-IP using a RNA fragment carrying only the HCV 3’-UTR 
To test if Ago2 is also recruited to the HCV 3’-UTR it was decided to perform anti-
Ago2-RNA co-IP assays using a RNA fragment derived from the pHCV 3’-UTR only 
plasmid, containing a small part of the luciferase ORF and the full HCV 3’-UTR. The 
protocol for those experiments was the same as for the 5’-UTR co-IP assays.  
In three out for four experiments no binding of Ago2 to the HCV 3’-UTR, neither in the 
presence (Figure 25 B, lane 4) nor in the absence of miR-122 (lane 5), was detected. 
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In one case a very weak band in the miR-122 positive sample appeared with no 
background in the miR-124 sample. As a positive control (lane 2) an anti-PTBP1 
antibody was used, since PTB was shown to strongly bind to the HCV 3’-UTR. 
In summary, these data suggests that Ago2 does not significantly bind to the HCV 
3’-UTR. This result was surprising due to the high degree of conservation and the 
positioning of the site. Since miR-122 forms an unusual complex at the HCV 5’-UTR, 
involving also sequence elements 5’ of the miR-122 binding sites (Machlin et al, 
2011) the question arose whether this might also be the case with the 3’-UTR.  
 
 
 
Figure 25: Anti-Ago2-RNA co-IP using HCV 3’-UTR with luciferase RNA. HeLa cells were 
transfected with radioactively labeled HCV 3’-UTRs including last 41 nts from the firefly 
luciferase open reading frame along with either miR-122 or miR-124, as a control. 6 h post-
transfection, the cells were lysed and 10 % of the lysate was saved as an input control (A). 
The rest of the lysate was used in anti-Ago2 immunoprecipitation. anti-PTBP1 and anti-FLAG 
antibodies were used as positive and negative control. After washing 10 % of the magnetic 
beads used for the precipitation were stored for Western Blot analysis (C). The co-
precipitated RNA was released from the proteins by Proteinase K digest, cleaned by 
chloroform - phenol extraction and precipitated with ethanol. The input controls were treated 
likewise. All RNAs were then separated on a 6 % Polyacrylamide gel with 7 M urea (B). 
Purified transcript was used as a marker for RNA integrity. The gel was subsequently dried 
and exposed to X-ray film.  
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2.4.2 Anti-Ago2 co-IP using a RNA fragment carrying parts of the NS5B ORF 
and the 3’-UTR 
Machlin and coworkers (Machlin et al, 2011) showed that in order to have an effect 
miR-122 not only needs to bind to the target region of its seed sequence but also 
needs to bind certain nucleotides further upstream of the binding site, forming a bulge 
at not paired areas.  
To see if there might be an additional binding area for miR-122 close to the 3’-UTR, 
for nucleotides of miR-122 not part of the seed sequence, a sequence comparison 
focusing on the 3’-end of the NS5B coding region was performed (Figure 26).  
 
 
 
Figure 26: Sequence comparison of the 3’-End of NS5B and parts of the variable 
region of five different HCV subtypes. Shown are the sequences of five different HCV 
subtypes, including the last stem loop of NS5B and the predicted miR-122 binding site in the 
variable region. The areas that form a stem are marked in grey. Highlighted in red are the 
regions that might serve as a binding site and extended binding area for miR-122. The stop 
codon of the HCV ORF is underlined. Also shown are the nucleotides of the miR-122 guide 
strand that would be used for the interaction.  
 
Interestingly four nucleotides were found (including two nucleotides of the stop 
codon) positioned in the non-paired region of a stem loop formed between the NS5B 
coding region and the variable region. These nucleotides might be able to pair with 
four nucleotides very close to the 3’-terminus of the miR-122 guide strand (Figure 
26). The identified sequence stretch belongs to two different codons in the HCV 
genome, coding for arginine and the translation stop.  
 
 
 
Figure 27: Comparison of the last two codons of the NS5B coding region of five 
different HCV subtypes. Given are the last two codons of the NS5B coding region of five 
different HCV subtypes. Highlighted in red are the nucleotides that possibly pair with parts of 
the miR-122 3’-end. The right box shows all possible codons for arginine and the codon 
usage in human cells (recalculated from Spencer, 2012). 
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Arginine is coded by six different codons, these six codons vary quite significantly in 
their usage in human cells (Figure 27, right side). Strikingly, only two of the six 
possible codons are used for the arginine in the predicted stem loop. More 
interestingly these are not the codons that display the highest codon usage rate 
(Figure 27). This led to the assumption that not only the arginine is critical at this 
position of NS5B, but also the sequence by which it is coded. 
 
 
 
Figure 28: Anti-Ago2-RNA co-IP using HCV 3’-UTR + NS5B loop RNA. HeLa cells were 
transfected with radioactively labeled HCV 3’-UTRs including the last 18 nts of the HCV 
NS5B open reading frame along with either miR-122 or miR-124, as a control. 6 h post-
transfection, the cells were lysed and 10 % of the lysate was saved as an input control (A). 
The rest of the lysate was used in anti-Ago2 immunoprecipitation. anti-PTBP1 and anti-FLAG 
antibodies were used as positive and negative control. After washing 10 % of the magnetic 
beads used for the precipitation were stored for Western Blot analysis (C). The co-
precipitated RNA was released from the proteins by Proteinase K digest, cleaned by 
chloroform - phenol extraction and precipitated with ethanol. The input controls were treated 
likewise. All RNAs were then separated on a 6 % Polyacrylamide gel with 7 M urea (B). 
Purified transcript was used as a marker for RNA integrity. The gel was subsequently dried 
and exposed to X-ray film. 
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To test this hypothesis it was decided to repeat the previous experiment now using 
RNA comprising the HCV 3’-UTR and the last stem loop of the NS5B coding region. 
This RNA was transcribed from a DNA template generated from the pHCV-FL 
plasmid by using a primer which paired at the start of the HCV 3’-UTR and also 
carried a long non-pairing region including the T7-RNA polymerase promoter and the 
last 18 nucleotides of NS5B sequence.   
 
The results of the experiments using this RNA construct are given in Figure 28. The 
experiment clearly shows a miR-122-dependent recruitment of Ago2 to the HCV 3’-
UTR (Figure 28, lane 4).This led to the conclusion, that the predicted additional miR-
122 binding region is really needed for efficient microRNA binding.  
 
2.5 Creation and characterization of mutants carrying insertions 
between the miR-122 binding sites of the HCV 5’-UTR and the IRES 
The HCV subtypes display a low variance concerning the spacing of structural 
elements that are important for translation. It seems that the miR-122 binding sites 
are positioned in a fixed distance relative to the IRES and it was wondered whether 
insertions between the IRES and the miR-122 binding sites might disrupt the 
stimulation effect of miR-122 on HCV translation. The hypothesis was that the fixed 
distance is necessary for proteins recruited by miR-122 to properly interact with the 
IRES elements or with the ribosomal subunits binding the IRES.  
 
2.5.1 Insertion of nucleotides between the miR-122 binding sites and the IRES 
Therefore mutants were created that carried insertions of either five, ten or twenty 
nucleotides (nts) in between the second miR-122 binding region and stem loop II 
which is the first stem loop belonging to the IRES. 
The insertions were introduced via  the Quick Chnage in vitro mutagenesis protocol. 
Two complementary mutagenesis primers that carried the desired insertion were 
used in the mutagenesis PCR, to amplify and mutagenize the pHCV-FL plasmid. The 
pHCV-FL construct that was used as a template was grown in Escherichia coli and 
thus was methylated by the Dam methylase. Using this fact it was possible to digest 
the initial template pHCV-FL in the PCR samples with the DpnI nuclease that only 
digests hemi-methylated DNA. The residual mutated DNA was subsequently 
transformed and amplified in bacteria. After small scale plasmid preparation (mini 
prep) the sequence of the three new plasmids, pHCV-FL 5nts, pHCV-FL 10nts and 
pHCV-FL stem, was confirmed by sequencing.  
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In silico analysis of the structure of the three mutants (Figure 29) revealed that the 
folding of the 5 nts insertion mutant was the same as the one of the wild type. For the 
10 and 20 nts mutants it could be seen that the miR-122 binding sites were partially 
(in case of the 10 nts mutant) or even completely (in case of the 20 nts mutant) 
integrated in a newly formed stem loop covering most of the miR-122 binding sites. 
Therefore, the pHCV-FL 20nts mutant was renamed pHCV-FL stem. 
 
 
 
Figure 29: Predicted folding of the HCV insertion mutants. In silico model of 5’-UTR of 
the 5 nts, 10 nts and the stem mutant compared to the wild type. The prediction comprises all 
nucleotides from the start to the 3’-base of stem loop II. Given in red are the positions of the 
two miR-122 binding sites. Colors indicate base pair probabilities. Program used was 
provided online (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). The parameter given were 
“minimum free energy and partition function”, “no dangling ends engery”, “Andronescu 
model, 2007” and “avoid isolated base pairs” at 37 °C.  
 
2.5.2 Testing of the insertion mutants in a luciferase reporter assay 
Despite the partial masking of the miR-122 sites in a stem loop for some of the 
mutants, it was decided to test them in a luciferase reporter assay to see if their 
translation was stimulated by miR-122. Those reporter assays were carried out by 
Florian Giering (Giering, 2013). After in vitro transcription, HuH-7 cells grown in a 
24-well tissue culture plate were transfected with 400 ng of the respective mutant 
RNA along with either 400 ng of miR-122 or miR-124. For normalization a capped 
and polyadenylated Renilla-luciferase expressing RNA was co-transfected. Cells 
were harvested and lysed 4 h post-transfection and the lysate was used in a 
luciferase assay.  
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As shown in Figure 30 B both the 5 and 10 nts insertion mutants are stimulated by 
miR-122 to a level similar compared to the wild type (Figure 30, B). This indicates 
that neither the insertion nor the partial masking of the miR-122 binding sites in case 
of the 10 nts mutant impaired miR-122 binding and a possible interaction of recruited 
proteins with the IRES. The stem mutant however proved to not be affected by 
miR-122. Thus leading to the assumption that miR-122 is not able to disrupt the stem 
loop and bind to its binding sites on the HCV mutant RNA. To explore this possibility 
it was decided to perform an anti-Ago2 a co-IP assay with this mutant and compare it 
to the wild type HCV RNA. If miR-122 is really not capable to bind to the stem mutant 
anymore the HCV stem RNA should not be coprecipitated along with Ago2.  
 
Figure 30: Luciferase assay using 
HCV mutants carrying insertions 
between the second miR-122 binding 
site and the IRES. (A) Schematic 
drawing of the 5 and 10 nts mutants and 
the stem mutant. The 5 and 10 nts 
mutants both carry an insertion of either 
5 or 10 nucleotides, between the second 
miR-122 binding site and the IRES. The 
stem mutant carries an artificial stem 
loop which comprises both miR-122 
binding sites and thus renders them 
unable to hybridize with miR-122. miR-
122 binding sites are highlighted in grey. 
(B) HuH-7 cells were transfected with a 
RNA reporter construct comprised of the 
open reading frame of the Firefly- 
luciferase (Fluc) and either the wild type 
(wt) HCV 5’-UTR or one of the mutations 
shown in (A). Furthermore, ectopic miR-
122 (or miR-124 as a control) and a 
capped and polyadenylated Renilla-
luciferase (RLuc) RNA were added to the 
samples. The RLuc values were used to normalize the measurements from the FLuc RNAs. 
The readouts from samples including the wild type 5’-UTR and miR-124 were set to 100 % 
and all other values were calculated relative to this sample. P-values were calculated using a 
student’s t-test (* = p< 0.05). Experiments were carried out by Florian Giering. Modified from 
(Conrad et al, 2013). 
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2.5.3 Anti-Ago2 co-IP assay using the 5’-UTR of the HCV stem mutant 
Finding out that the translation of the HCV stem mutant RNA is not stimulated by 
miR-122 it was decided to check whether miR-122 is even able to bind to this mutant. 
Therefore, an anti-Ago2 co-IP assay was performed to see if Ago2 is also recruited to 
the HCV stem 5’-UTR in the presence of miR-122. It was reasonable to assume that 
if miR-122 was not able to bind to the mutant, Ago2 binding would be impaired as 
well. 
 
 
 
Figure 31: Anti-Ago2-RNA co-IP using HCV 5’-UTR stem mutant RNA. HeLa cells were 
transfected with radioactively labeled HCV 5’-UTRs carrying the stem mutation along with 
either miR-122 or miR-124, as a control. Furthermore, a set of cells was transfected with wild 
type HCV 5’-UTRs and either miR-122 or miR-124, to directly compare the binding 
efficiencies of the wild type RNA versus the stem mutant RNA. HCV 5’-UTR-386 RNA was 
used as wild type control. 6 h post-transfection, the cells were lysed and 10 % of the lysate 
was saved as an input control (A). The rest of the lysate was used in anti-Ago2 
immunoprecipitation. anti-eIF3a and anti-FLAG antibodies were used as positive and 
negative control. After washing 10 % of the magnetic beads used for the precipitation were 
stored for Western Blot analysis (C). The co-precipitated RNA was released from the proteins 
by Proteinase K digest, cleaned by chloroform - phenol extraction and precipitated with 
ethanol. The input controls were treated likewise. All RNAs were then separated on a 6 % 
Polyacrylamide gel with 7 M urea (B). Purified transcript was used as a marker for RNA 
integrity. The gel was subsequently dried and exposed to X-ray film. 
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Following the previously described protocol for a Ago2 specific co-IP RNA fragments 
were used that comprised the 5’-UTR of the stem mutant and compared to the wild 
type HCV 5’-UTR in the presence or absence of miR-122 (Figure 31).  
The results clearly show that for the stem mutant RNA the binding of Ago2 is 
massively impaired (Figure 31, B, lane 4) compared to the wild type (Figure 31, B, 
lane 6). The band derived from the sample containing miR-122 and the mutant RNA 
is just insignificantly stronger than the background in the samples containing the 
control miR-124 (Figure 31, B, lanes 5 and 7). 
Therefore, it was concluded that masking the miR-122 binding sites in the stem loop 
interferes with Ago2 binding to the HCV 5’-UTR most likely by preventing miR-122 to 
interact with its complementary sequences. 
Now that a translationally competent mutant RNA that does not efficiently bind 
miR-122 was available, it was wondered whether this mutant would also show a 
lower stability in cells compared to the wild type HCV RNA in presence of miR-122. 
 
2.5.4 Comparison of the stability of the wild type HCV RNA and the HCV stem 
mutant 
Shimakami and coworkers proposed that the stimulation of HCV translation and 
replication by miR-122 could be a secondary effect. They assumed that the main 
impact of miR-122 is to protect the HCV RNA from degradation (Shimakami et al, 
2012a). To check this hypothesis HuH-7 cells were transfected with reporter 
constructs coding for the firefly luciferase (Fluc) that carried either the wild type HCV 
5’-UTR or the stem mutant 5’-UTR. Additionally ectopic miR-122 or miR-124 was 
added. The cells were harvested after 3, 6 or 9 h after transfection and a luciferase 
assay was performed.  
The Fluc measurements from this experiment should directly represent the amount of 
RNA present in the cells. On the one hand, if miR-122 protects the HCV RNA from 
degradation a slower decrease in luciferase activity in the wild type 5’-UTR with miR-
122 (wt/miR-122) sample should be detected compared to the samples containing 
the stem mutant or miR-124. On the other hand, a higher luciferase activity in the 
wt/miR-122 sample compared to the wild type with miR-124 with nearly the same 
relative drop in luciferase activity over time would argue for a stimulating effect of 
miR-122 on HCV translation.  
Figure 32 shows the results of this assay. All values were calculated relative to their 
respective 3 h measurement which was set to 100 % for each kind of sample. In the 
presence of either microRNA, the stem mutant showed an average decrease of 
about 53 % in the two 3 h intervals between the first and the last time point. The 
sample containing wild type and miR-124 (wt/miR-124) lost in average 36 % 
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luciferase activity in a 3 h period, showing a shallow decline of about 27 % in the first 
3 h and a steeper one of about 45 % in the second 3 h. The difference in the decline 
between the stem mutant and the wt/miR-124 sample is supposedly due to the fact 
that HuH-7 cells have a natural background of miR-122 which can bind to the wild 
type HCV RNA in the wt/-miR-124 sample. The wt/miR-122 sample however shows 
no loss in reporter activity between the first two time points, but later a decrease of 
about 35 % could be detected. These results show that the interaction of miR-122 
and its binding sites really seems to contribute to HCV RNA stability over time. 
 
 
Figure 32: Stabilization effect of miR-122 on HCV RNA. Huh- 7 cells were transfected with 
either wild type HCV FL or the stem mutant RNA along with miR-122 or miR-124, 
respectively. After 3, 6 and 9 hours the cells were harvested and lysed. The lysate was then 
used to perform a luciferase assay. The 3 hour values for all RNA combinations were set to 
100 %. For statistical purpose a two-way ANOVA with a 95% confidence interval was carried 
out using PRISM 5.0. 
 
 
Nevertheless, this effect does not seem to be the only effect of miR-122. After 
normalization of all measurements relative to the 3 h time point of wt/miR-122 (Figure 
33) there is a significant gap between the luciferase activities of wt/miR-122 and the 
wt/miR-124 at the 3 h time point. According to Shimakami et al. the half-life of HCV 
RNA in presence of miR-124 is 3.6 h (Shimakami et al, 2012a). Since equal amounts 
of RNA were transfected into the cells, this difference of translation efficiency of 
about 70 % between the wt/miR-122 and the wt/miR-124 sample at the 3 h time point 
can’t be explained by RNA decay alone. Such a large difference in luciferase activity 
short after transfection is most likely explained by differences in translation efficiency 
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of the respective RNA invoked by miR-122. Thus it seems that besides stabilizing the 
HCV RNA, miR-122 also stimulates translation efficiency.  
 
 
 
 
Figure 33: Translational effect of miR-122 on HCV RNA. Huh- 7 cells were transfected 
with either wild type HCV FL or the stem mutant RNA along with miR-122 or miR-124. After 
3, 6 and 9 hours the cells were harvested and lysed. The lysate was then used to perform a 
luciferase assay. All values were normalized relative to the measurement of wild type with 
miR-122 sample at the 3 h time point. 
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3 Discussion 
 
The data presented in this work show that microRNA-122 (miR-122) recruits proteins 
of the Argonaut (Ago) family, Ago1 and Ago2, to the HCV 5’-UTR. For Ago2 it could 
also be shown that this protein interacts with a binding site in the variable region (VR) 
of the HCV 3’-UTR in a miR-122-dependent manner. This binding however, seems to 
be dependent not only on the binding of the seed sequence of miR-122 but also on 
the hybridization of nucleotides close to the 3’-end of the miR to the HCV RNA. Four 
nucleotides were identified in the HCV NS5B coding region that seem to be 
necessary for efficient miR-122 binding to the HCV 3’-UTR. Furthermore, the 
experiments presented in the previous chapters give hint that miR-122 binding to the 
HCV RNA has two effects. Firstly, the binding of miR-122 seems to prolong the half-
life of HCV RNA most likely by protecting it from degradation. Secondly, the data 
shows that upon binding miR-122 enhances HCV translation efficiency. Thus, it 
seems that there are at least two different mechanisms in place through which miR-
122 is able to positively influence the life cycle of HCV.  
 
3.1 Recruitment of Ago proteins to HCV RNA 
The purpose of this work was to investigate whether Ago proteins directly bind to 
HCV RNA in a microRNA-122 dependent manner. For Ago1 and Ago2 a miR-122-
dependent recruitment to the HCV 5’-UTR could be established, for Ago2 also a miR-
122-dependent binding to the HCV 3’-UTR was found. These data correlate with the 
findings of Shimakami and coworkers (Shimakami et al, 2012a), who also found an 
association of these two Ago proteins with the HCV RNA in the presence of miR-122. 
Furthermore, it was shown that Ago1 seems to associate less efficiently with HCV 
RNA than Ago2, which is supported by Shimakami et al. (Shimakami et al, 2012a). 
However, neither my experiments nor their data give any explanation whether the 
difference in Ago protein binding to HCV RNA is due to a lower abundance of Ago1 
compared to Ago2 in the cells or if this is a specific effect. Roberts and coworkers 
showed that knock out (KO) of Ago1 or Ago2 had a strong negative effect on HCV 
translation stimulation by miR-122, with only a slightly stronger influence seen with 
the Ago2 KO (Roberts et al, 2011). It is possible that Ago1 plays a more important 
role in the action of miR-122 on HCV translation than the binding experiments 
suggest.  
In addition, Roberts et al. showed that KO of all four Ago proteins resulted in only a 
small additional decrease of HCV translation stimulation by miR-122 compared to 
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Ago2 KO alone (Roberts et al, 2011). In comparison, Randall et al found that KO of 
Ago4, which is the least abundant Ago protein in humans, had the biggest negative 
impact of all the Ago proteins on HCV RNA abundance and production of infectious 
virus (Randall et al, 2007). Based on the latter findings, it could be speculated that 
different Ago proteins influence the HCV lifecycle at several stages. Whether the 
influence of Ago proteins on HCV replication is directly or indirectly mediated by other 
miRs is not yet clear. 
 
3.2 Effect of miR-122 binding to HCV RNA  
The data presented in this work suggests that HCV RNA is stabilized by the binding 
of miR-122. It was found that the wild type HCV RNA reporter construct, in the 
presence of a control miR or a mutant deficient for miR-122 binding, display a much 
more pronounced drop in luciferase activity over time than the wild type HCV reporter 
RNA in the presence of miR-122. Using the luciferase activity as a direct measure of 
RNA abundance in transfected cells, it could be shown in a time course assay that 
the average decrease in luciferase activity for the mutant HCV RNA construct in the 
presence of miR-122 or miR-124 and for the wild type HCV reporter RNA in the 
presence of miR-124 ranges around 35 - 53 % in a 3 h period. For the wild type HCV 
RNA in the presence of miR-122 no reduction in luciferase activity was found during 
the first 3 h and only a 35 % decrease in reporter activity in the second 3 h interval. 
These data correlate well to the calculated half-life (t1/2) of HCV RNA of 
approximately 3.6 h in the presence of miR-124 published by Shimakami et al. 
(Machlin et al, 2011; Shimakami et al, 2012a). However, Shimakami and coworkers 
calculated the half-life of HCV RNA in presence of miR-122 to be 5.3 h. This result 
differs a bit from the data shown in this work where a decrease of luciferase activity 
of about 35 % in 9 h was measured. This discrepancy might be due to the differences 
in the testing system. Shimakami et al. checked directly for HCV RNA abundance, 
whereas measuring luciferase activity as an indicator for RNA stability could proof to 
be less accurate in the long run due to possible differences in t1/2 of the HCV RNA 
and the luciferase. 
Due to the stabilization of HCV RNA by miR-122, it was assumed that miR-122 might 
act as a homologue of a Cap-structure on HCV RNA protecting it from degradation 
(Roberts et al, 2011; Shimakami et al, 2012a). Adding a translationally inactive non-
methylated guanosine Cap analog to the 5’-end of the HCV RNA Shimakami et al. 
did not see any difference in stability in the presence or absence of miR-122. 
Furthermore, they were not able to detect stimulation of translation by miR-122 for 
this RNA.  
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Contrary to the findings by Shimakami and coworkers (Shimakami et al, 2012a), the 
data presented here in this work suggests that there might also be a moderate effect 
of miR-122 on HCV translation. A difference of approximately 70 % in translation 
efficiency in the sample with wild type HCV RNA and miR-122 and the sample with 
miR-124 was found. Since this difference occurs only 3 h after transfection, RNA 
degradation cannot be the exclusive explanation for it. It can rather be assumed that 
this difference occurs due to variations in the inherent translation efficiency of the 
HCV reporter RNA in the presence of miR-122 compared to miR-124. This indicates 
that miR-122 has a moderate, but direct influence on HCV translation, which is not 
due to stabilization of HCV RNA by miR-122. This idea is supported by the finding 
from the group of Catherine Jopling who found that the binding of miR-122 to its 
target sequences in the HCV 5’-UTR has a positive effect on translation only when 
the complete HCV IRES is present. For these experiments Roberts et al. exchanged 
the HCV IRES by the IRES elements of either the structurally similar IRES of the 
classic swine fever virus (CSFV) or the IRES of foot and mouth disease virus 
(FMDV). The results showed no positive effect of miR-122 on translation in both 
cases. Not even a chimeric IRES derived from HCV and CSFV could rescue miR-
122-dependent translation stimulation (Roberts et al, 2011). Recently two other 
papers from different groups gave rise to the assumption that binding of miR-122 to 
the HCV 5’-UTR might induce structural changes in the IRES. Performing in vitro 
structural analysis with the HCV IRES in presence and absence of miR-122 both 
groups found that binding of miR-122 changes the accessibility of several nucleotides 
in the in structures known to be necessary for HCV translation. For example a the 
area around the translation start codon as well as nucleotides in the loop region of 
stem loop (SL) II showed decreased reactivity whereas parts of the stem regions of 
SLII and IV became more accessible (Mortimer & Doudna, 2013; Pang et al). 
Strikingly, SLII and IV are both necessary for efficient initiation of translation and the 
areas of both loops that showed a lower reactivity upon miR-122 binding were 
described to interact with each other (Filbin & Kieft, 2011). Thus it seems that miR-
122 binding might induce and alteration in the structure of the HCV IRES leading to 
an increase in translation. 
 
3.3 Impact of RNA stabilization on control samples during Ago-specific 
co-IP assays 
Despite the fact that the data from the time course experiments suggest a 36 - 53 % 
decrease in HCV RNA abundance during 3 h it is surprising to see no differences 
between the anti-Ago2 co-IPs input control samples with HCV RNA and miR-122 
present compared to the ones with HCV RNA and miR-124. Based on the data 
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gathered from the time course experiments, that suggest an increase in the half-life 
for HCV RNA in the presence of miR-122 during the first 6 h, it would be expected to 
see the difference in HCV RNA abundance between the miR-122 and miR-124 co-IP 
input sample on the gels. However, no difference in the ability to stabilize HCV RNA 
between miR-122 and miR-124 was observed. 
There have been reports that liposome-mediated transfection of eukaryotic cells, 
which was used for the experiments, might pose problems. It has been described that 
fractions of the transfected RNAs do not get properly transported into the cells but 
rather accumulate in punctuate structures inside and outside the cell where the RNA 
stays biologically inactive (Barreau et al, 2006). During cell harvest those inactive 
RNAs mix with the portion of RNAs that got properly transported into the cytoplasm 
and might falsify results on stability. However, Roberts et al. reported no significant 
difference in RNA abundance between liposome-mediated transfection and 
electroporation when using HCV RNA reporter constructs containing the firefly 
luciferase ORF flanked by the HCV 5’- and 3’-UTR (Roberts et al, 2011). Since the 
RNA fragments used for co-IP were derived from a very similar construct, it could be 
possible that the reason why no difference between the miR-122 and miR-124 co-IP 
input sample could be observed is not due to a bias stemming from the method of 
transfection.  
A possible explanation for the same abundance of HCV RNA in the presence of miR-
122 and miR-124 comes from the fact that for the experiments only small fragments 
of HCV RNA (comprising only the 5’- or 3’-UTR) have been used. These RNA 
fragments are highly structured and contain several stem loops. Furthermore, it is 
known that these structures are tightly packed with proteins, possibly making them 
less accessible to RNases compared to longer RNAs and protecting them from 
efficient degradation. Such an explanation is supported by the results gathered 
during the co-IP experiments in which two versions of the HCV 5’-UTR were used. 
One 5’-UTR comprised 386 nucleotides and also included parts of the firefly 
luciferase ORF. The other HCV 5’-UTR fragment was shortened by 23 nts and thus 
contained only HCV specific sequences. Using the HCV 5’-UTR construct, that 
contained parts of the firefly luciferase ORF, two bands of different sizes were 
detected in the miR-122 co-IP sample. When a shortened HCV RNA fragment which 
excluded the firefly luciferase part was used, only one band occurred in the co-IP 
sample. This observation gave rise to the assumption that the luciferase part of the 
fragment was degraded, whereas the HCV specific part was protected from RNases. 
These findings suggest that the HCV RNA fragments used for co-IP assays are more 
stable than the HCV RNA reporter constructs used during the time course 
experiments, and thus show no difference in HCV RNA abundance 6 h post-
transfection. 
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3.4 Binding of Ago2 to the HCV 3’-UTR 
 
Figure 34: Schematic depiction of the 
binding sequences for miR-122 
present in the HCV 3’-UTR and NS5B 
coding region. Shown is the positioning 
of the two regions (grey) necessary for 
miR-122 binding in the 3’-UTR and NS5B 
coding region of HCV. The sequence of 
those binding sites is derived from the 
HCV 1b Con1 isolate. In red the position 
of the translation stop of the polyprotein 
ORF is given. 
 
 
 
The binding of miR-122 to the HCV 5’-UTR is peculiar. It has been shown that in 
addition to the seed sequence other nucleotides of miR-122 are also involved in the 
binding to the target sequences on HCV RNA. In the case of the first miR-122 binding 
site on the HCV RNA (the one closer to the 5’-end), the nucleotides 14-17 of miR-122 
are hybridizing to the first 4 nucleotides of the HCV RNA. In case of the second miR-
122 binding site in the HCV 5’-UTR the nucleotides 14-16 of the miR interact with 
three nucleotides directly behind the first miR-122 binding site. This unusual binding 
of miR-122 leads to the formation of a bulge and a tail region on the miR (Machlin et 
al, 2011). In vitro data suggests an even more pronounced binding of miR-122 to the 
second binding site, involving even more nucleotides outside of the seed sequence 
than described by Machlin et al. Mortimer and coworkers proposed that additionally 
to the seed sequence and nucleotides 14-16 also the nucleotides 10 and 12 could 
hybridize to the HCV RNA. Thus, the G residue at position 10 of miR-122 would bind 
to position 37 of the HCV 5’-UTR and the C at position 12 of the miR could pair to a 
G at position 34 of the HCV RNA (Mortimer & Doudna, 2013). It is unclear however 
whether this binding also occurs under in vivo conditions, when in addition to miR-
122 also proteins are recruited to the HCV 5’-UTR. 
The data gathered from anti-Ago2 - HCV RNA co-IP experiments suggest that an 
unusual complex between miR-122 and the HCV RNA is not only formed at the HCV 
5’-UTR but also during binding of miR-122 to a highly conserved miR-122 binding site 
in the variable region of the HCV 3’-UTR. My data indicates that for efficient binding 
of miR-122 to this site in the variable region additional nucleotides, present in a stem 
loop in the coding region of NS5B, are necessary (Figure 34).  
These four nucleotides, comprising parts of the stop codon of the polyprotein open 
reading frame, hybridize to the nucleotides 17-20 of miR-122. This binding would 
lead to the formation of a large bulge of eight nucleotides and a very small tail region 
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of two nucleotides on miR-122. Until now this binding site present in the variable 
region of the 3’-UTR was not shown to be functionally relevant for the HCV life cycle 
(Henke et al, 2008; Nasheri et al, 2011), but a majority of studies focused exclusively 
on the two miR-122 binding sites present in the 5’-UTR. However, Nasheri et al. 
analyzed the accessibility and affinity of the miR-122 binding sites on HCV RNA for 
miR-122 in vitro and found that the site in the variable region of the 3’-UTR showed a 
higher affinity for miR-122 binding compared to the second site in the 5’-UTR. 
Furthermore, they identified a fourth miR-122 binding site located in the coding region 
of NS5B (Figure 35) and postulated that this binding site might be a repressor for 
HCV translation and replication with a high affinity for miR-122 (Nasheri et al, 2011). 
It would be worthwhile to investigate whether the binding of miR-122 to this fourth 
miR-site also leads to the same unusual complex formation as the one seen with 
miR-122 binding to the 5’-UTR and supposedly to the 3’-UTR.  
 
 
 
Figure 35: Localization of miR-122 binding sites in the HCV genome. This graphic shows 
the localization of the four identified miR-122 binding sites (grey) on the HCV genome. Two 
are situated in the 5’-UTR upstream of the IRES. A third binding site was predicted in the 
variable region (VR) of the 3’-UTR and a newly found fourth miR-122 binding site (Nasheri et 
al, 2011) is located in the NS5B coding region of the polyprotein ORF. The numbers signify 
the first and the last nucleotide that is part of the binding site in the HCV 1b Con1 isolate.  
 
3.5 Relocation of cellular proteins during HCV infection 
It is known that during infection HCV remodels the host cell to fit its purpose. For 
example HCV interferes with P-body and stress granule formation by recruiting 
several proteins localized in these compartments to lipid droplets (LDs) (Ariumi et al, 
2011a). Amongst those are DDX3 and 6, ATX2, PABP1 and G3BP1. Furthermore, 
components involved in miR maturation, like Ago2 and Dicer, have also been shown 
to be redirected to LDs during infection (Berezhna et al, 2011). LDs are believed to 
take part in viral RNA synthesis and virion assembly due to their association with 
virus components like the Core protein and NS5B (Lindenbach, 2013; Lohmann, 
2013).  
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Knock out (KO) studies revealed that some of the P-body and stress granule proteins 
redirected to LDs have impact on the HCV life cycle. KO of PABP1, ATX2, DDX3 and 
DDX6 lead to a dramatic drop in HCV RNA abundance and protein synthesis, 
especially in case of DDX6 (Ariumi et al, 2011a). The DEAD-box helicase and 
supposedly RISC component DDX6 (Chu & Rana, 2006) was recently in the focus of 
investigation since it was reported that DDX6 influences HCV translation and 
replication (Scheller et al, 2009). The fact that DDX6 is able to interact with Ago2 
gave rise to the question whether DDX6 takes part in the translation stimulation of 
HCV by miR-122. Recent studies however, formed the general opinion that DDX6 
influences HCV translation and replication in a miR-122-independent manner (Huys 
et al, 2013; Jangra et al, 2010). Even though DDX6 does not seem to be part of the 
miRNP complex necessary for HCV translational stimulation, the need for DDX6 for 
efficient gene silencing by miR-122 (Huys et al, 2013) supports the idea that the 
miRNP complex recruited for increasing HCV translation differs from the one 
recruited for RNA silencing.  
 
3.6 Influence of other microRNAs on the HCV lifecycle 
In addition to remodeling the cell for its advantage, several publications indicate that 
HCV infection can alter the miR expression profile of the host cell (Bhanja 
Chowdhury et al, 2012; Bruni et al, 2011; Ishida et al, 2011; Liu et al, 2010; Shwetha 
et al, 2013; Zhang et al 2013). Some of these miRs have been assumed to have 
influence on HCV replication as well as to modulate the response of the immune 
system of the host. For instance it has been demonstrated that HCV influences the 
host cell immune response, apoptosis and proliferation pathways by stimulating the 
expression of miR-491, miR-320c and miR-473-5p. Notably miR-491 and miR-320c 
have been predicted to act on the PI3/Akt signaling pathway and thus are assumed 
to modulate the host cell response to HCV infection (Ishida et al, 2011; Shwetha et 
al, 2013). Shwetha and coworkers furthermore reported that miR-320c and miR-483-
5p seem to have putative targets in the Map-kinase and NFκB signaling pathways 
and thus seem to take part in the regulation of apoptosis, immune response and cell 
proliferation (Shwetha et al, 2013).  
The effect of another microRNA, miR-130a, on HCV remains controversial. Liu et al. 
as well as Zhang and coworkers reported that miR-130a is down regulated in HCV 
infected cells (Liu et al, 2010; Zhang et al, 2013), whereas Bhanja Chowdhury and 
coworkers showed an up-regulation of miR-130a by HCV. In addition, Bhanja 
Chowdhury et al. demonstrated that sequestration of miR-130a resulted in a lower 
replication efficiency of HCV, which is most likely due to repression of the interferon-
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induced transmembrane protein, IFITM1, a protein known for its antiviral function 
(Bhanja Chowdhury et al, 2012). 
In contrast to the miRs described above, several other miRs have been reported to 
have negative effects on HCV replication. For example, Murakami et al. predicted a 
binding site for miR-199a* in stem loop II of the HCV 5’-UTR which is part of the HCV 
IRES. It was shown that the inhibition of HCV replication by miR-199a* seems to be 
accomplished by recruitment of the RISC (Murakami et al, 2009). Pedersen et al. 
identified two IFN-inducible miRs, miR-196 and miR-448, which have binding sites in 
the HCV genome and which down regulate HCV replication (Bruni et al, 2011; 
Pedersen et al, 2007). For miR-196 Bruni et al. reported that HCV negatively effects 
the expression of this miR (Bruni et al, 2011).  
In addition, the miR-30(a-d) cluster as well as miR-130a, miR-192, miR-301 and miR-
324-p5 have been shown to be down-regulated by HCV infection and up-regulated in 
response to IFN-α (Liu et al, 2010; Zhang et al, 2013). It has been shown that down-
regulation of miR-30c enhances HCV genome replication. Furthermore, some of 
these miRs are assumed to have impact on endocytosis as well as TGF-β signaling, 
a pathway involved in cell growth and apoptosis (Zhang et al, 2013) .  
Overall, the observed alterations in miR expression in the host cell induced by HCV 
infection seem to facilitate HCV reproduction as well as to maintain its persistence. 
Understanding how HCV influences miR expression in the host cell might be 
advantageous for developing new antiviral drugs, by either sequestering miRs that 
are hijacked by the virus or by supplementing miRs that are down-regulated during 
HCV infection. The sequestration approach was recently tested for miR-122 in a 
phase 2a trial with promising results concerning viral clearance and emergence of 
viral resistance (Janssen et al, 2013).  
 
3.7 Current model of miR-122 action on HCV RNA 
The current model, based on the data presented in this work, is shown in Figure 36. It 
implies that miR-122 recruits a miRNP complex, including the Ago proteins, to the 
HCV 5’-UTR by interacting with the two miR-122 binding sites. This binding does not 
only involve the seed sequence of the miR but also several nucleotides downstream 
of the seed region, thus protecting the HCV RNA from degradation by cellular 
RNases. Furthermore, binding of miR-122 to HCV RNA enhances translation 
efficiency. It is assumed that this stimulation occurs at the step of translation 
initiation, possibly by interaction of proteins that are part of the miRNP complex with 
the translation initiation machinery. Several groups reported that for the stabilization 
of HCV RNA and translational enhancement the tail region of miR-122 bound to the 
5’-UTR seems to play a major role (Machlin et al, 2011; Roberts et al, 2011; 
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Shimakami et al, 2012a). The nucleotides 20-23 of miR-122 have been shown to be 
important for HCV translation stimulation and RNA abundance, but were dispensable 
for translational repression by the RISC complex (Machlin et al, 2011; Roberts et al, 
2011). In this context it would be interesting to identify the components of the 
microRNA-protein (miRNP) complex which is supposedly recruited by miR-122. It is 
reasonable to assume that the composition of the stimulating miRNP complex differs 
from the repressive one.  
Another explanation for HCV translation stimulation by miR-122 could be that binding 
of the miRNP complex alters the structure of the IRES changing its binding affinity for 
other cellular factors that influence translation. Such a model would accommodate 
data from the Niepmann group which suggest that miR-122 binding to HCV RNA 
competes with the binding of the heat shock cognate protein 70 (HSC 70) (Henke, 
2010). HSC 70 has been shown to associate with HCV particles and seems to be 
involved in the assembly and budding of HCV (Parent et al, 2009). Thus it could be 
possible that HSC 70 only binds HCV genomes that show a conformation not 
favorable for translation but rather genomes that are ready to be incorporated into 
viral particles. 
 
Figure 36: Model: The effect of miR-122 on 
HCV translation and replication through 
binding to the HCV 5’-UTR. miR-122 is loaded 
into a miRNP complex and recruits this complex 
to the HCV 5’-UTR. When bound to the HCV 
RNA, the miRNP complex protects HCV RNA 
from degradation but also interacts with the HCV 
IRES or factors bound to it and thus stimulates 
HCV translation. 
 
 
 
 
 
 
 
 
 
 
For the binding of miR-122 to the HCV 3’-UTR no biological function has been 
described so far. In one of the few approaches to elucidate the function of this miR-
122 binding site Henke, Goergen et al. found that mutating the binding site for miR-
122 in the 3’-UTR had no effect on HCV translation stimulation by miR-122 but 
showed changes in overall translation efficiency possibly caused by altering the 
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structure of the VR (Henke et al, 2008). For these experiments the authors used a 
reporter constructs containing the firefly luciferase ORF flanked by the HCV 5’- and 
3’-UTR. This construct however lacked the nucleotides in the HCV NS5B coding 
region that have been identified to be necessary for efficient miR-122 and Ago2 
binding. Since the results presented in this thesis suggest that the miR-122 binding 
site in the HCV 3’-UTR also includes parts of the NS5B coding region of HCV, it 
might be worthwhile to revisit the question whether this miR-122 binding site 
influences HCV translation stimulation by miR-122. For this purpose a reporter 
construct should be created that comprises an ORF coding for a reporter protein 
prolonged by the last nucleotides of the NS5B coding region, thus including the last 
two codons of NS5B and the stem loop in which they are located.  
 
In summary, the data presented in this work supports the idea that miR-122 positively 
influences HCV taking part in at least two different mechanisms. By recruiting a 
miRNP complex in which the ago proteins are involved in miR-122 prolongs the half-
of HCV RNA as well as stimulates translation. It can only be speculated on how much 
each of the miR-122 binding site in the 5’-UTR adds to each of these mechanism. It 
could be possible that due to their position and binding behavior the first site protects 
the HCV 5’-end from degradation and the second site is involved in translation 
stimulation. The questions however, whether both of these miR-122 binding sites are 
bound by a miRNP complex at the same time and what biological function the binding 
of miR-122 to the third binding site in the VR of the 3’-UTR has, stay to be answered.  
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4 Methods and Materials  
 
4.1 Methods 
 
4.1.1 Tissue Culture Techniques 
All steps involving eukaryotic cells were carried out in using a biosafety cabinet 
(BSC), sterile pipettes and pipette tips, as well as sterile buffers and media. All 
pipettes and pipette tips contained filters to eliminate any carryover of aerosols. All 
buffers and media were warmed to 37 °C before use. Everything that was carried into 
the BSC was decontaminated by wiping it down with 70 % denatured ethanol.  
To properly identify the cells all cultures were marked with name of the cell line, date 
and passage number. The Lot number from the ECACC was also included if 
available.  
 
4.1.1.1 Thawing of eukaryotic cells that were stored in a liquid nitrogen tank 
To thaw cells stored in liquid nitrogen it is necessary to work carefully. The use of 
protective eyewear as well as gloves is recommended since nitrogen may reside in 
the vial.  
The cryotubes were partially opened in a BSC to release any residual nitrogen. 
Following this the cryovials were placed in a 37 °C water bath to accelerate the 
thawing process. The cells were then transferred to a 25 cm2 tissue culture flask 
containing 5 ml of pre-warmed Dulbecco’s Modified Eagles Medium supplemented 
with 10 % fetal bovine serum (FBS) and 1 % Penecillin/Streptomycine (Pen/Strep) 
(DMEM 10 %) and incubated at 37 °C for several hours until they adhered to the 
bottom of the flask. When the cells have attached the medium was changed to fresh 
DMEM 10 %. This change of medium is necessary to remove cells that died during 
the freezing and thawing procedure, as well as to remove residual DMSO that was 
part of the freezing medium. 
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4.1.1.2 Passaging eukaryotic cells 
To ensure a constant growth of an adherent cell line it is necessary to split the cells 
on a regular basis to keep them from getting too confluent. Cell cultures that are 
grown too thickly have the tendency to detach from the growing surface and to die.  
Usually cells were passaged when they reached 80 % - 95 % confluency to ensure 
that they are in the log phase of growth. 
The old culture medium was discarded and the cells were washed twice with PBS. 
Afterwards, the cells were treated at 37 °C with an appropriate amount of 0.5 % 
Trypsin-EDTA until they detached (for 75 cm2 flasks 3 ml Trypsin were used, for 175  
cm2 flasks 5 ml Trypsin were used). Trypsin was inactivated by adding at least the 
same amount of fresh DMEM 10 %. 
The cells were resuspended in the DMEM 10 % by pipetting up and down. 
Subsequently, an appropriate amount of cell suspension was given into a new flask 
along with fresh DMEM 10 % and cultured for several days. A normal amount of 
HeLa cells that was given into the new flask was 1/20 – 1/30 of the cell suspension 
for 4 days of cultivation.  
 
4.1.1.3 Counting eukaryotic cells 
To determine the total amount of cells in a cell suspension the cells were counted 
using a Neubauer improved hemocytometer. The counting chamber has a depth of 
0.1 mm and is divided into several squares of different sizes. For determining the cell 
number the squares of 1 mm2 (Figure 37, highlighted in blue) were counted. Cells 
that touched the upper or right edge of the square were not included in the 
calculations. Cells touching the left or lower edge of the square were included into the 
count. The total cell number of all four 1 mm2 squares was averaged and this mean 
value was multiplied by 10000, resulting in the number of cells per ml.  
 
Figure 37: Partition of a Neubauer improved 
hemocytometer. The hemocytometer has a depth of 0.1 
mm and is divided in several squares ranging from 0.0025 
mm2 to 1 mm2. The square used to determine the amount of 
cells in a suspension is highlighted in blue and has an area 
of 1 mm2. The count of four of these 1 mm2 squares was 
averaged and multiplied by 10000 to approximate the total 
number of cells per ml. Cell touching the right and upper rim 
of the square were not counted. The picture was taken from 
http://www.microbehunter.com and modified.  
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4.1.1.4 Seeding eukaryotic cells 
For all experiments HeLa or HuH-7 cells were seeded in either 24-well plates or 6-
well plates or 9 cm dishes. The cells were washed twice with PBS and detached with 
0.5 % Trypsin EDTA. Afterwards the cells were resuspended in an appropriate 
amount of DMEM 10 %, usually leading to a final volume of 10 - 15 ml. Subsequently, 
the cells were counted using a Neubauer improved hemocytometer. After counting, a 
certain amount of cell suspension was diluted in DMEM 10 % and seeded in the 
desired tissue culture plate size. The appropriate amounts of cells have been 
determined for every cell line by previous empiric testing. Since the growth rate 
varies during the life of a cell line it may be necessary to reconsider the appropriate 
amount of cells once in a while, depending on the number of passages and general 
treatment of the cell line. The final volumes of cell suspension with DMEM 10 % in 
the wells of the tissue culture plates were 1 ml for 24-well plates, 3 ml for 6-well 
plates and 10 ml for 9 cm dishes. 
 
4.1.1.5 Transfection of eukaryotic cells using Lipofectamine 2000 
Eukaryotic cells were transfected by using Lipofectamine 2000 (Invitrogen) 
transfection reagent. This reagent contains liposomal particles that can bind nucleic 
acids and shuttles them into the cells via endocytosis.  
A ratio of 1:3 between transfection reagent and nucleic acids (µg RNA/DNA : µl 
Lipofectamine 2000) was established as used for optimal transfection efficiency of 
both HeLa and HuH-7 cells. 
Two samples were prepared: one containing RNA/DNA diluted in DMEM, and one 
containing Lipofectamine 2000 also diluted in DMEM. The appropriate amount of 
DMEM in those samples varied depending on the size of the tissue culture plate on 
which the cells were grown; for 6-well plates 250 µl DMEM was used for each sample 
and for 9 cm dishes 500 µl DMEM were used.  
The two samples containing RNA/DNA and Lipofectamine 2000, respectively, were 
incubated for 5 minutes at room temperature and then merged together by pipetting. 
The resulting mixture was incubated for additional 20 minutes at room temperature 
without agitation. Meanwhile the cells were washed twice with PBS and fresh DMEM 
without any supplements was added. Again, the amount of DMEM varied depending 
on the size of the tissue culture plate, for 6-well plates 500 µl and for 9 cm dishes 4 
ml DMEM were used. 
After incubation the transfection mixture containing both RNA/DNA and 
Lipofectamine 2000 was added drop wise to the cells. Afterwards the cells were 
incubated at 37 °C with 5 % CO2 for 3 - 6 hours. 
  Methods and Materials 
58 
When the incubation time for the transfection before harvesting the cells is 9 hours or 
less all these steps can be carried out without a BSC. 
 
4.1.1.6 Freezing eukaryotic cells 
Eukaryotic cells change their behavior with the number of passages and the time 
they are cultured. Sometimes transfection efficiencies and growth rate can drop 
dramatically. At this time point it is necessary to thaw new cells that were stored in 
the vapour phase of a liquid nitrogen tank. To ensure that low passage cells are 
always available it is obligatory to propagate and freeze some of the freshly thawed 
cells from time to time.  
Generally the protocol to freeze cells given by the ECACC was used. The 
cryomedium was made by mixing 20 % FBS with 10 % DMSO as a cryoprotectant. 
The cells were grown in DMEM 10 % until they reached log phase growth at 
approximately 80 - 90 % confluency. The old culture medium was discarded, the cells 
were washed twice with PBS and treated with 0.5 % Trypsin-EDTA until they 
detached. The trypsination was stopped by adding one volume cryomedium. 
Subsequently, the cells were centrifuged for 10 minutes at a speed of 150 rcf and 
4 °C. The cells were resuspended in cryomedium at a concentration of about 2 - 4 x 
106 cells per ml and dispersed in to cryovials, 1 ml per vial. 
The cryovials were placed in an alcohol bath (Nalgene cell freezing container 
containing 100 % Isopropanol) that was pre-cooled to 4 °C. The cells were then 
placed in a -80 °C freezer. After one to two days the cryovials were transferred into 
the gas phase of a liquid nitrogen tank.  
A week after the freezing one sample of the cells was thawed and tested if the cells 
were still viable. 
  
  Methods and Materials 
59 
4.1.2 Microbiological Methods  
All steps involving bacteria were carried out in close proximity to a Bunsen burner to 
ensure sterility of the bacterial culture. Metal and glass ware such as glass pipettes 
or beakers were either disinfected by dry heat sterilization or were singed. The 
surface of the working space was disinfected by wiping it down with 70 % ethanol.  
 
4.1.2.1 Cultivation of bacteria 
Bacteria were grown either on agar plates forming colonies or in LB medium as a 
solution.  
The powdered LB medium was solved in deionized water according to the 
manufacturer’s specifications and autoclaved. For agar plates, 3.75 g of bactoagar 
were added per 250 ml of LB medium before autoclaving.  
For seeding bacteria on a petri dish, the agar was heated and cooled down to 
approximately 60 °C, and only then was the antibiotic added (7.5 µg/ml). Following 
the addition of the antibiotic about 20 ml of the agar were poured into a petridish. 
After turning solid the bacteria were dropped on the agar and spread with a bacterial 
spreader until the liquid seeped into the plate. 
For liquid cultures it was usually necessary to prepare a pre-culture containing 3 - 5 
ml of LB medium (7.5 µg ampicillin /ml). This pre-culture was inoculated with one 
bacterial colony picked from an agar plate and grown for several hours until the 
medium turned turbid (approximately OD 0.6), then 1/10 of this culture was used to 
inoculate a bigger flask of LB medium, ranging in size from 10 ml - 500 ml. 
 
4.1.2.2 Transformation of bacteria by electroporation 
For transformation either the E. coli strains XL1-Blue or HB101 were used. The 
bacteria were prepared for electroporation by growing a 10 ml culture over night at 37 
°C under constant agitation (180 - 250 rpm). To remove any residual salts that might 
interfere with the electroporation the bacteria were centrifuged at 5000 rcf for 15 
minutes at 4 °C and the pellet was resuspended in ice-cold double distilled 
autoclaved water (ddH2O). This step was repeated 3 times. After the third 
centrifugation the pellet was resuspended in 2 ml ice-cold ddH2O and the bacteria 
were divided in 100 µl aliquots. These aliquots could be stored at -80 °C for several 
weeks.  
For electroporation one aliquot was thawed on ice and mixed with approximately 100 
ng of plasmid DNA or half the volume of a ligation sample (usually 7.5 µl). Afterwards 
the mixture was pipetted into an electroporation cuvette, into which an additional 500 
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µl dd H2O were added to ensure that enough volume resided in the cuvette. Cells 
were electroporated at 25 µF, 200-400 Ohm and 2.5 kV. Immediately after 
electroporation 1 ml of LB medium was added to the cells and the bacteria were 
incubated for 1 hour at 37 °C under constant agitation (180 - 250 rpm). 
Subsequently, transformed bacteria were spread on an agarplate containing an 
appropriate antibiotic, usually ampicillin.   
 
4.1.2.3 Alkaline lysis of bacteria and plasmid preparation  
The alkaline lysis of bacteria and plasmid preparation is a standard procedure in 
molecular biology laboratories to amplify plasmid DNA (Sambrook et al, 1989). 
Bacteria were transformed with the plasmid of choice and grown (usually overnight) 
at 37 °C under constant shaking at 180 – 250 rpm until they reached log phase 
growth (approximately OD 0.6). 
Afterwards the cells were pelleted by centrifugation (5000 rcf, 4 °C, 10 – 15 minutes) 
and lysed under alkaline conditions in the presence of SDS, thus denaturing all 
bacterial DNA and proteins. Neutralization was accomplished by adding a potassium 
acetate containing buffer. This neutralization leads only the relatively small plasmid 
DNA to properly renature, all other cell components form a white fall out that can be 
easily removed from the sample either by centrifugation or filtration. Following the 
removal of the cell debris, the plasmid DNA was bound to a silica matrix at high salt 
and low pH conditions. After washing with an ethanol containing buffer, the DNA was 
eluted with an elution buffer into a fresh collection tube and precipitated by adding 
isopropanol. Small scale preparation protocols usually directly elute the DNA with 
ddH2O, the precipitation step was then omitted.  
This method was employed for two different scales of bacterial cultures, leading to 
different amounts of plasmid gained from the procedure. The first scale, maxi 
preparation, used 100 - 250 ml of bacterial culture and was performed with the 
NucleoBond AX 100 Kit from Machery-Nagel. The second scale, mini preparation, 
used 2 ml of a 3 - 5 ml culture and was carried out with the Wizard Plus SV Minipreps 
DNA purification System from Promega. Both kits provided all buffers, components 
and instructions necessary for the protocol.  
 
 
 
  Methods and Materials 
61 
4.1.3 Methods concerning the Manipulation and Characterization of Nucleic 
Acids 
4.1.3.1 Working with RNA 
RNases are ubiquitous proteins that are not completely inactivated by normal means 
of heat sterilization methods like autoclaving.  Therefore, it is necessary to take 
certain precautions when working with RNA. At least the use and the regular 
changing of latex or nitrile gloves is recommended.  
All glass and metal ware was baked at either 500 °C for 4 hours or overnight at 280 
°C.  Reusable plastic ware was soaked for 1 hour in 0.1 M NaOH and 1 mM EDTA 
solution and subsequently rinsed with ddH2O. Additionally, everything was wrapped 
or covered with aluminum foil to prevent RNase contamination and autoclaved.  
Chemicals used to prepare buffers were specially dedicated to RNA work and only 
touched with RNase free material, like baked spatula. For weighing these chemicals 
the RNase-free aluminum wrapping of the used spatula was employed as a scale 
pan.  
All self-made buffers (except gel running buffers like TBE or TAE) were prepared in 
and after preparation filled into RNase-free glass ware and subsequently autoclaved.  
Furthermore, only nuclease-free certified filter tips and sterile serological pipettes 
were used to handle the buffers and RNA solutions.  
 
4.1.3.1 DNA-template preparation for in vitro transcription 
Since none of the plasmids coding for the used RNA reporter constructs contained a 
T7 or Sp6 RNA polymerase terminator sequence at which the elongation of the 
nascent RNA molecule could stop (e.g. the authentic end of the HCV 3’-UTR could 
not be guaranteed), it was necessary to prepare a DNA template for in vitro 
transcription (4.1.3.2). To ensure that the T7 or Sp6 RNA polymerase did not add 
nucleotides to the HCV 3’-UTR a primer was used for amplification that comprised 
the last 29 nucleotides of the 3’-UTR.  
The tables show the standard program employed on the Biometra TProfessional 
cycler as well as the composition of the sample. Cycle steps 2 - 4 were repeated 30 
times. The choice of primers used for each PCR depended on the plasmid used as a 
PCR template.  
During the work for this thesis the vendor of the Taq DNA polymerase changed (from 
Promega to NEB), which lead to some changes in the PCR protocol. The elongation 
and final elongation temperature was decreased to 68 °C (initially 72 °C). The 
addition of MgCl2 to the sample was omitted and the concentrations of the dNTPs, 
the primers and the Taq DNA polymerase were decreased. 
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After PCR the resulting DNA fragments were purified either by phonol-chloroform 
extraction (4.1.3.7) with subsequent ethanol precipitation (4.1.3.8) or following the 
protocol of Illustra GFX PCR DNA and Gel Band Purification Kit from GE Healthcare 
and eluted in ddH2O.  
 
 
Table 2: Program and sample composition for DNA-template preparation 
 
4.1.3.2 In vitro transcription of radioactive and non-radioactive RNA  
To provide RNA constructs for transfection of eukaryotic cells (4.1.1.5) an in vitro 
transcription was performed using a PCR derived DNA template (4.1.3.1). The in vitro 
transcription was carried out at 37 °C for 1.5 hours using T7 or Sp6 RNA polymerase. 
Transcription buffer was provided by Fermentas and contained 200 mM Tris-HCl (pH 
7.9), 30 mM MgCl2, 50 mM DTT, 50 mM NaCl and 10 mM spermidine. Since DTT is 
not stable for a long time, 10 mM DTT were added in case the transcription buffer 
was older than one month.  All components were pipetted at room temperature for 
the reason that spermidine may precipitate the DNA template at low temperatures. 
The concentrations of all components used for transcription are given below. For 
labeling the RNA product with radioactive Uridine residues, the concentration of 
rUTPs was reduced to 100 µM and 0.625 µM of α-32P rUTPs were added. Non-
radioactive RNA was purified by either phenol-chloroform extraction (4.1.3.7) or using 
the Qiagen RNeasy RNA clean-up protocol following the manufacturer’s 
specifications. After purification the concentration of RNA was measured by 
photometric measurement using the Tecan Infinite multimode reader.  
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The amount of radioactively labeled RNA was determined by separating it on a 
denaturing polyacrylamide gel (4.1.3.10) and estimating the percentage of 
incorporated radioactive nucleotides. The ratio of incorporated and free radioactive 
nucleotides was used to calculate the concentration of the labeled RNA. 
 
total amount of RNA [pMol] = (c (rUTP) [µM] x reaction volume [µl] x incorporated radioactive 
rNTPs [%]) / (incorporated radioactive rUTPs [%] + nonincoporated radioactive rUTPs [%]) x 
number rUTPs in RNA 
 
component  amount 
DNA template 100 – 200 ng 
Transcription Buffer 1x 
DTT* 10 mM 
rNTPs (AGCU) / rNTPs (AGC)** 0.5 mM (each) 
rUTPs** 100 µM 
α-32P rUTPs** 0.625 µM 
T7 / Sp6 RNA polymerase 0.1 U/µl 
 
*  added when the transcription buffer was older than one month 
** used only for radioactive labeling of the RNA product 
 
Table 3: Sample composition for radioactive and non-radioactive in vitro transcriptions 
 
4.1.3.3 In vitro mutagenesis  
The in vitro mutagenesis is a technique used to easily introduce point mutations or to 
create small insertions or deletions into plasmid DNA, by amplifying the plasmid. This 
mutagenesis strategy is based on the commercially available QuickChange 
mutagenesis protocol by Stratagene.  
The mutagenesis is accomplished by performing a PCR using two complementary 
primers which both carry the desired mutation. The primers should have 25 - 45 nts 
length and a Tm of 78 °C or above. The mutation should be in the middle of the 
primers flanked by 10 to 15 nts of correct sequence to each side. 
In the first round of amplification the primers anneal leaving an unpaired bulge at the 
site where the mutation will be introduced, the polymerase will then create newly 
synthesized mutated DNA strands. During the second and all following rounds of the 
PCR these new strands will be exponentially amplified. Since the not mutated 
template DNA was isolated from E. coli it was methylated by the Dam methylase. 
These methylations are recognized by the endonuclease DpnI. The not methylated 
PCR products are not used as a substrate for degradation. Using DpnI it is possible 
to remove the wild type DNA from the PCR sample. A small portion the PCR product 
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before and after DpnI digest is analyzed on an agarose gel (4.1.3.9). Bands on the 
gel with the DpnI digest signified that the PCR was successful. The mutated DNA 
was transformed (4.1.2.2) into either E. coli XL1-Blue or HB101.  
This method requires the use of a high fidelity DNA polymerase like the Pfuturbo from 
Stratagene or the Phusion polymerase from Finnzymes, to ensure that no further 
mutations are introduced during amplification of the plasmid. We used the Pfuturbo 
polymerase for the in vitro mutagenesis. Note that by changing the polymerase 
changes to the PCR program may apply.   
The tables below show the standard sample composition and PCR protocol.  
 
component  amount 
DNA template  * 5 - 50 ng 
dNTPs 0.2 mM (each) 
Primer 1 125 ng 
Primer 2 125 ng 
Pfuturbo buffer 1x 
Pfuturbo polymerase  ** 2,5 U 
H2O @ 50 µl 
 
*  usually three samples were prepared for each mutation since the ratio of template to primes is a critical step in this method 
** added later after first denaturation step 
 
Table 4: sample composition for mutagenesis  
 
 
1 99 °C  2 min initial denaturing 
2 90 °C  2 min (addition of Pfuturbo) pause to add polymerase 
3 95 °C  30 s denaturing 
4 55 °C 1 min annealing 
5 68 °C  1 min / kb of plasmid length elongation 
6 68 °C  5 min final elongation 
7 8 °C  pause storage 
 
Table 5: standard in vitro mutagenesis PCR program  
 
The steps 3 to 5 were repeated 18 times. For difficult mutations a slightly different 
PCR cycle protocol was employed. A cycle with a lower annealing temperature (44 
°C) was introduced into the program and repeated for 10 times. Subsequently, a 
cycle with an annealing temperature of 55 °C was repeated for 20 times. The 
changes in the program are given in the table below.  
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1 99 °C  2 min initial denaturing 
2 90 °C  2 min (addition of Pfuturbo) pause to add polymerase 
3 * 95 °C  0.5 min denaturing 
4 * 40°C 45 s annealing 
5 * 68 °C  2 min / kb of plasmid length elongation 
3 ** 95 °C  0.5 min denaturing 
4 ** 55 °C 45 s annealing 
5 ** 72 °C  1 min / kb of plasmid length elongation 
6 72 °C  10 min final elongation 
7 8 °C  pause storage 
 
*  repeated 10 times **  repeated 20 times 
 
Table 6: Modified in vitro mutagenesis PCR program for difficult mutations 
 
4.1.3.4 Two-step in vitro mutagenesis 
The two-step in vitro mutagenesis is a method employed when introducing lager 
insertions or deletions into plasmid DNA.  
For this protocol two pairs of primers are needed. Figure 38 schematically shows the 
procedure. One primer of each pair (primers 2 and 3) carries the desired mutation 
flanked at the 3’-end by approximately 10 to 20 nts of correct sequence. These 
primers have to be also partially complementary to each at the 5’-ends so that they 
can hybridize on a length of at least 10 nucleotides.  
 
Figure 38: Model of 
the two-step 
mutagenesis PCR. In a 
first step the mutations 
were introduced by two 
separate PCRs using 
mutagenesis primers 1 
and 2 for the first PCR 
and primers 3 and 4 for 
the second PCR 
reaction (A). The 
resulting DNA fragments 
of both PCRs partially overlap and can be used as a template for a third PCR (B) in which 
the primers 1 and 4 are used to fill in the gaps and amplify the mutated final fragment. 
 
During the first step each primer pair is used to amplify two DNA fragments both 
carrying parts of the mutated region at their 5’-end. In the second step the two 
amplified fragments are combined and serve as a template for a PCR in which the 
two flanking primers (primers 1 and 4) not carrying the mutation are used to complete 
and amplify the mutated DNA fragment. The length of the final product was checked 
on an analytical agarose gel (4.1.3.9) and the fragment was cloned into a vector 
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backbone by restriction digest (4.1.3.5) using restriction sites near the end of the final 
PCR product and ligation (4.1.3.6). 
 
4.1.3.5 Restriction digest of DNA 
Restriction digests are usually used to provide DNA molecules with “sticky ends” for 
subsequent ligation or to check identity and integrity of DNA plasmids. Therefore, 
DNA molecules are incubated in certain buffers in the presence of restriction 
endonucleases. These nucleases can be obtained from several distributers like NEB 
or Fermentas.  
The volume of the digest is highly variable depending on the amount of DNA that 
should be digested and the downstream application. Usually a sample has a final 
volume of 50 µl. The buffers needed are provided with the enzyme by the 
manufacturer and were used according to the manual’s specifications.  
The amount of enzyme needed was calculated from the following formula: 
amount of enzyme [µl] = 
number of restriction sites in target molecule [pmol] / specific enzyme activity [pmol hits/µl]  
Amounts calculated from this formula that were lower than 0.5 µl were rounded up to 
0.5 µl since the used pipettes were not trustworthy with lower volumes.  
Digests with multiple enzymes (double digests) were carried out following the 
suggestions provided by either thermoscientificbio.com/webtools/doubledigest/  or 
neb.com/tools-and-resources/interactive-tools/double-digest-finder. 
The restriction was usually carried out in a water bath for 1 hour. The temperature of 
the incubation was dependent on the respective enzymes.  
After digest the sample or a small portion of it was analyzed on an agarose gel 
(4.1.3.9) to check the sizes of DNA fragments after the digestion.  
 
4.1.3.6 Ligation of DNA fragments 
To fuse two different DNA molecules a ligation using the T4 DNA ligase was carried 
out. This enzyme catalyzes the formation of phosphordiester bonds between the 5’-
phosphate of one and the 3’-OH of the other DNA molecule by hydrolyzing ATP. This 
reaction is more reliable when using DNAs with “sticky ends”, meaning DNAs 
carrying residues of the same restriction site at its respective ends. 
A typical ligation reaction of 20 µl for cloning an insert into a vector backbone 
contained 25 ng of vector. The amount of insert depends on its length and the size of 
the vector. The necessary amount of insert was calculated by the following formula:  
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amount of insert [ng] = 5 x amount of vector [ng] x length of insert [bp] / length of vector [bp]  
The concentration of the DNA fragments was assessed by photometric measurement 
in combination with gel analysis (4.1.3.9).  
Besides the vector and the insert the ligation reaction also contained 400 U of the T4 
DNA ligase and 1 x ligase reaction buffer. The ligation occurred at room temperature 
for 1 hour or overnight at 4 °C. After ligation the ligase was inactivated at 65 °C for 10 
minutes when the resulting DNA was transformed into bacteria (4.1.2.2).  
 
4.1.3.7 Phenol-chloroform extraction  
This procedure is used to remove proteins from nucleic acids. During the protocol the 
watery sample containing nucleic acids and proteins is mixed with organic solvents, 
phenol and chloroform, and then centrifuged. After centrifugation two phases occur, a 
watery and an organic one. The nucleic acids remain in the watery phase; the 
proteins are denatured and partially solved in the organic phase.  
The watery sample was mixed with one volume of Rotiphenol and vortexed for 
approximately 30 seconds. Subsequently, the watery phase of the sample (usually 
the upper phase depending on the salt concentration) was transferred into a new 
reaction tube. Next, one volume of a mixture (1:1) of phenol and chloroform / isoamyl 
alcohol (24:1) was added. After vortexing the sample was centrifuged again and the 
upper watery phase was transferred into a new reaction tube. The chloroform serves 
as a solvent for fatty acids. The isoamyl alcohol is added for a clearer phase 
separation.  
In the last step of the extraction the sample was mixed with one volume of chloroform 
/ isoamyl alcohol (24:1) for a final separation. In this step, the chloroform serves to 
remove traces of phenol from the watery sample. The watery phase was transferred 
into a new reaction tube. All centrifugation steps were carried out at 13000 rcf at 
room temperature for 5 minutes. Usually this procedure was followed by an ethanol 
precipitation (4.1.3.8) to concentrate the nuclei acids and to remove salt 
contaminations from the sample. 
 
4.1.3.8 Precipitation of nucleic acids with ethanol  
The ethanol precipitation was used to concentrate and clean nucleic acids of salt 
contaminations stemming from reaction buffers.  
The sample is thoroughly mixed with three volumes of 99 % ethanol and 1/10 volume 
of 3 M sodium acetate. When low amounts of nucleic acids were expected 1 - 2 µl of 
Glycoblue (15 mg/ml) were added to increase the visibility of the expected RNA or 
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DNA pellet. For precipitation the mixture was incubated for one to several hours at -
20 °C. After incubation the sample was centrifuged at 17000 rcf and 4 °C for 30 
minutes. Following which the supernatant was carefully removed and discarded. 
Subsequently, the pellet was washed twice with 70 % ethanol and air-dried at 37 °C 
until the pellet changed color from milky white to transparent. At this step it was 
necessary to make sure that no ethanol remained with the pellet. The pellet was then 
dissolved in ddH2O. The amount of ddH2O depended on the expected RNA or DNA 
concentration and the intended downstream applications. 
. 
4.1.3.9 Separation of nucleic acids on an agarose gel  
Non-radioactively labeled RNAs and DNAs were separated on a 1 -2 % TAE agarose 
gel depending on the expected size of the nucleic acid. Upon solidifying the agarose 
forms a sieve like structure. When an electric current is applied to the gel the 
negatively charged nucleic acids will move though the gel. Small fragments will pass 
thought the gel more quickly than larger ones, thus, the separation is based on the 
size of the nucleic acids. The resulting bands in the gel can be visualized by staining 
the gel with intercalating agents like ethidium bromide or cyber green and exposing it 
to UV light.  
The samples were mixed with RNA or DNA sample buffer containing xylencyanole 
and bromphenol blue. These dyes served as a visual measure for fragment migration 
on the gel. Then the samples were loaded onto the gel and run at 100-150 V. 1 x 
TAE was used as a running buffer. When the bromophenol blue front reached the 
lower third of the gel, the run was stopped. Afterwards, the gel was incubated in a 
TAE - ethidium bromide bath for 10 - 30 minutes and subsequently exposed to UV 
light. 
From preparative agarose gels the desired bands were cut out during UV-light 
exposure and the nucleic acids were purified using the Illustra GFX PCR DNA and 
Gel Band Purification Kit, following the manufacturer’s protocol. Since UV light may 
lead to mutations in DNA it was necessary to reduce the time of exposure for cutting 
out the bands to a minimum.  
 
4.1.3.10 Separation of radioactively labeled RNA on a polyacrylamide gel  
To separate radioactively labeled RNAs the RNA was mixed with RNA sample buffer 
and loaded on a 6 -10 % polyacrylamide in TBE buffer gel with 7 M urea. An electric 
current of 100-150 V was then applied. Usually the gel was run until the xylencyanol 
band from the sample buffer reached the end of the gel. Gels that were used for 
estimating the RNA amount after in vitro transcription were run until the bromophenol 
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blue front reached approximately the middle of the gel, to ensure that the free 
nucleotides did not exit the gel. 1x TBE was used as a running buffer. After 
separation the RNA fragments were visualized by exposing them to X-ray film for 
several minutes up to several days. When low amounts of radioactivity were 
expected in the gel the exposure was amplified by putting the X-ray cassette in which 
the film was exposed at -80 °C. 
For long time exposure (more than 1 hour) it was necessary to dry the gel before 
exposing it to the film. Therefore the gel was fixed with a 7.5 % acetic acid and 5 % 
ethanol fixer solution for 15 minutes, put on a piece of  3MM chromatography paper 
and dried for 2 hours at 80 °C on a gel dryer.  
 
4.1.3.11 Preparation of duplex microRNAs 
For transfection of eukaryotic cells double stranded microRNAs were required. To 
produce these miR duplexes the mature miR strand (miR mat, 100 µM) and the miR 
passenger strand (miR *, 100 µM) were mixed (1:1). Afterwards the sample was 
incubated in a PCR cycler starting at 90 °C and decreasing the temperature by 1 °C 
per minute to a final temperature of 4 °C. After cycling the sample was split into 
aliquots of 10 or 20 µl and stored at -20 °C.  
 
4.1.4 Protein Biochemical Techniques 
4.1.4.1 Argonaute protein specific RNA co-immunoprecipitation 
The Argonaute (Ago) protein specific RNA co-immunoprecipitation (co-IP) was used 
to detect interaction of the Ago protein family members with parts of the HCV RNA in 
presence or absence of miR-122. The Ago proteins were pulled down from a crude 
cell extract containing radioactively labeled HCV RNA fragments. The pull down was 
accomplished by binding the proteins to specific antibodies coupled to magnetic 
beads. If HCV RNA and Ago proteins interact the HCV RNA is co-precipitated and 
could be detected by autoradiography.  
First, 50 - 100 µl of magnetic protein A or G beads were washed with 500 µl PBS and 
resuspended in 1000 µl of PBS. The magnetic beads made it possible to use 
magnetic separation of the beads from a suspension without the need for 
centrifugation after washing steps. After washing the beads, antibodies were added 
and the suspension was rotated at 4 °C overnight (it was possible to shorten this step 
to 2 hours if necessary). The appropriate amount of antibody had to be determined 
for each antibody by testing during the run of the experiments; Table 7 shows the 
respective antibodies and the concentration at which they were used.  
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Second, a 9 cm dish of 80 - 90 % confluent HeLa cells was transfected (4.1.1.5) with 
1 - 3 µg of radiolabeled RNA fragments comprising either the HCV 5’-UTR or 3’-UTR 
and the same amount of miR-122 or miR-124 as a control. 15 µl of the HCV RNA 
fragments stock (RNA transcript) were saved as a marker for RNA length. 6 hours 
post transfection the cells were washed twice with 1 ml of PBS and lysed on plate in 
1 ml co-IP Lysis Buffer for 30 minutes at 4 °C. Meanwhile the antibody coupled 
beads were pelleted at 1000 rcf and 4 °C for 1 minute, washed once with co-IP wash 
buffer and resuspended in 500 ml PBS. After lysis the sample was centrifuged at 
17000 rcf and 4 °C for 30 minutes to clear it from cell debris. 10 % of the lysate were 
saved as an input control to check the equal distribution of HCV RNA in the different 
samples and stored at 4 °C. The rest of the lysate was given to the antibody coupled 
magnetic beads. The samples were rotated at 4 °C for 3 hours. Next, the beads were 
pelleted at 1000 rcf and 4 °C for 1 minutes and the supernatant was discarded. 
Subsequently the beads were washed 4 times with 1 ml co-IP wash buffer, 
resuspended in 1 ml PBS and transferred to a new reaction tube. Before the PBS 
was discarded 10 % of the sample were saved as a control to check the efficiency of 
Ago binding in the samples by SDS-PAGE (4.1.4.3) and Western Blot (4.1.4.4).  
Afterwards, 250 µl of proteinase K buffer and 10 µl of proteinase K [20 mg/ml] were 
added to the beads and the input sample. The samples were incubated at 65 °C for 
15 minutes. To ensure that the beads did not sediment at the bottom of the reaction 
tube during the incubation, the tubes were flicked every 5 minutes. Meanwhile 235 µl 
proteinase K buffer were added to the saved 15 µl of the RNA transcript.  
After incubation all samples, including input and RNA transcript, were centrifuged 
(1000 rcf, 4°C, 1 minute) and thoroughly mixed with 300 µl phenol. A centrifugation 
was carried out at 17000 rcf and 4 °C for 10 minutes, and the watery upper phase 
was transferred to a new reaction tube. Subsequently, the samples were mixed with 
300 µl of chloroform and again centrifuged (17000, rcf 4°C, 10 minutes). The upper 
phase was then collected and an ethanol precipitation (4.1.3.8) was performed.  
The resulting RNA pellets were thoroughly resuspended in 30 µl (co-IP samples) or 
100 µl (input and transcript) of RNA sample buffer by pipetting and analyzed on a 
denaturing polyacrylamide gel (4.1.3.10).  
For the RNA transcript and input controls it was necessary to heat the samples 
several times to 60 °C to accomplish satisfying resuspension. Before running the gels 
the input samples were diluted 1:100 in RNA sample buffer and 10 µl (0.1% of the 
total input sample) of this dilution were loaded on the gel. The RNA transcript was 
diluted 1:500 in RNA sample buffer and 10 µl of this dilution (~0.003 % of the original 
RNA transcript) were used for the co-IP sample gel, while 30 µl (~0,009 % of the 
original RNA transcript) were used for the input sample gel.  
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antibody Amount per 100 µl   
magnetic beads 
concentration magnetic 
beads  
rat-anti-Ago2 clone 11A9 5 µl ~1,5 mg/ml protein G 
rat-anti-Ago1 clone 4B8 5 µl ~1,5 mg/ml protein G 
rabit-anti-eIF3a * 5 µl 0.2 mg/ml protein A 
goat-anti-PTBP1 5 µl 0.5 mg/ml protein G 
mouse-anti-FLAG 5 µl ~3.8 mg/ml protein G 
 
* for eIF3a only 50 µl beads were used per sample 
 
Table 7: Amount of antibodies used for anti-Ago – HCV RNA co-IPs 
 
4.1.4.2 Immunoprecipitation 
Immunoprecipitation (IP) was used to pull down proteins of interest using a specific 
antibody. The procedure can basically be divided into two parts, first the pre-clearing 
of the cell lysate and second the IP-step to pull out the desired protein. To prepare 
the lysate, a 9 cm dish of ~80 % confluent cells was washed twice with PBS and 
harvested in 800 µl IP-lysis buffer with a cell scraper. Following this the debris was 
pelleted by centrifugation (17000 rcf for 10 minutes at 4°C). Subsequently, the lysate 
was transferred into a new reaction tube. For the pre-clearing step, the cell lysate 
was rotated at 4 °C for 1 hour with native magnetic beads (25 µl beads per 200 µl 
lysate) to remove proteins biding unspecifically to the beads. After pre-clearing the 
beads were removed by centrifugation and the lysate was transferred into a new 
reaction tube containing new magnetic beads with the specific antibody. The IP 
occurred at 4 °C for 2 hours under constant rotation. Afterwards the beads were 
washed twice with IP/co-IP wash buffer and once with PBS. The proteins were 
released and denatured by adding 50 µl SDS sample buffer and heating the sample 
for 10 minutes at 95 °C. Finally, the proteins were analyzed by SDS-polyacrylamide 
gel (4.1.4.3) and Western Blot assay (4.1.4.4).  
The amount of antibody and beads varied according to the amount of cells and the 
abundance of the protein of interest. For the anti-Ago2 IP 300 µl of the rat-anti Ago2 
clone 11A9 hybridoma supernatant and 100 µl of magnetic protein G beads were 
used.  
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4.1.4.3 SDS-polyacrylamide gel electrophoresis (PAGE) of proteins 
The SDS-polyacrylamide gel electrophoresis was based on the protocol described by 
Laemmli in 1970 (Laemmli, 1970). The bipartite SDS-PAGE is composed of the 
upper stacking gel and the lower resolving gel. The stacking gel has a pH of 6.8 and 
it also carries the wells for the samples. The resolving gel has a pH of 8.8 and usually 
takes up about 2/3 of the total gel. The proteins are denatured and linearized by SDS 
contained in the sample buffer and the running buffer. SDS leads to constant charge 
to mass ratios for different protein species in the sample. Thus the movement of the 
proteins towards the anode depends only on their size (ie, molecular weight). The 
running buffer contains glycine which at the pH of 6.8 in the stacking gel is mainly 
present in its zwitterion form and chloride ions (CL-). Due to its zwitterionic form the 
glycine moves slowly though the stacking gel in comparison the negatively charged 
Cl- ions which move much quicker. This leads to a zone of low ionic strength which is 
also a zone of high electric field strength in which the proteins move close to the 
glycine front. This leads the proteins to enter the resolving gel at virtually the same 
time. At pH 8.8 in the resolving gel the glycine deprotonates letting it run faster, thus, 
the field of low ionic strength dissipates and the proteins can separate depending on 
their size. 
For the experiments the gels were poured following the instructions given in 
“Molecular cloning – a laboratory manual” by Sambrook, Fritsch and Maniatis (book 
3, page 18.52, “Solution for Preparing Resolving Gels for Tris-Glycine SDS-PAGE”). 
The table below gives the recipe for the most commonly used acrylamide gel 
percentages.  
 
 Stacking gel  Resolving gel  
 5 % 8 % 10 % 12 % 
H2O  1.4 ml 2.3 ml 1.9 ml 1.6 ml 
30 % Bisacrylamide (19:1) 0.33 ml 1.3 ml 1.7 ml 2.0 ml 
1.5 M Tris-HCl pH 6.8 0.25 ml    
1.5 M Tris-HCl pH 8.8  1.3 ml 1.3 ml 1.3 ml 
SDS 10 %  0.02 ml 0.05 ml 0.05 ml 0.05 ml 
APS 10 %  0.02 ml 0.05 ml 0.05 ml 0.05 ml 
TEMED 0002 ml 0.005 ml 0.005 ml 0.005 ml 
total  2 ml 5 ml 5 ml 5 ml 
 
Table 8: Composition for SDS-PAGE stacking and resolving gels of different percentages 
 
The samples for the SDS-PAGE were cooked at 95 °C for 10 minutes in the 
presence of SDS sample buffer, usually at a ratio of 1:1 (sample:sample buffer). 
Afterwards, the samples were shortly spun down to collect it at the bottom of the 
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reaction tube and pipetted into the wells of the gel. The gel was run at 100 - 180 V, 
until the bromphenol blue front from the sample buffer exited the gel. Usually a SDS-
PAGE was followed by a Western Blot assay (4.1.4.4) 
 
4.1.4.4 Western Blot  
The Western Blot is used to detect proteins by a set of two antibodies. The primary 
antibody binds to the protein in question; the secondary antibody is covalently linked 
to a horseradish peroxidase and binds specifically to the Fc-part of the primary 
antibody. The peroxidase is in the run of the experiment used to oxidize a substrate 
that then emits light. This chemiluminiscence can then be detected by X-ray films.   
In the first step of the procedure the proteins that were separated on a SDS-
polyacrylamide gel (SDS-PAGE) (4.1.4.3) are transferred on a Polyvinylidenfluoride 
(PVDF) membrane by semi-dry electroblotting. Therefore, a 9 x 6 cm PVDF 
membrane is activated by immersing it in 100 % methanol for 1 minute and placed in 
the blotting chamber along with the gel. The blotting chamber was assembled in the 
following order: Three pieces (9 x 6 cm) of 3MM chromatography paper (Whatman 
paper) soaked in anode buffer, three pieces of Whatman paper soaked in anode 
buffer II, membrane, SDS-PAGE and three layers chromatography paper soaked in 
cathode buffer. It is necessary to make sure that no bubbles are between the 
different layers of paper, membrane and gel, otherwise some regions of the gel might 
not be blotted to the membrane.  
After assembly an electric current of 43 mA per membrane is applied for 1.5 hours. 
After transfer the membrane is blocked in TBST with 10 % (w/v) dry milk (blocking 
buffer). The blocking is carried out under constant rocking either for 1 hour at room 
temperature or overnight at 4 °C.  
Subsequently, the blocking buffer was discarded and the membrane was stained with 
an appropriate primary antibody in blocking buffer. Incubation with the primary 
antibody was performed at room temperature for 1 hour under constant agitation. 
Afterwards the antibody solution was discarded and membrane was washed thrice 
with TBST for 10 minutes.  After washing the membrane was rocked for 1 hour in the 
secondary antibody solution, containing the peroxidase coupled antibody and 
blocking buffer. Finally the membrane was washed thrice with TBST and twice with 
TBS, each step taking 10 minutes. The SuperSignal West Femto Chemiluminescent 
substrate from Pierce was then added to the membrane, following the manufacturer’s 
specifications. Therefore, the membrane was placed in a cut open, transparent 
plastic bag and 1 ml of the substrate was pipetted on top of it. Subsequently, the bag 
was closed and the membrane was incubated for 5 minutes at room temperature. 
After incubation the substrate was removed by wiping it out thoroughly and the bag 
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was sealed. Afterwards the membrane was exposed to x-ray film for several seconds 
to several hours.  
The table below gives the antibodies and at what dilutions they were usually used.  
 
Primary Antibody Manufacturer  Dilution  
rat-anti-Ago2 clone 11A9, 
hybridoma supernatant  
G. Meister  1:50 
rat-anti-ago2 clone 11A9, 
purified antibody 
Sigma Aldrich  1:1000 – 1:3000 
rat-anti-Ago1 clone 4B8 Sigma Aldrich 1:1000 
   
Secondary Antibody Manufacturer Dilution  
goat-anti-rat POD, light chain 
specific  
Jackson ImmunoResearch 1:20000 
 
Table 9: Antibodies and dilutions used for Western Blot analysis 
 
4.1.4.5 Firefly Luciferase Assay 
During the luciferase assay luciferin is converted into oxoluciferin by the luciferase of 
common eastern firefly (Photinus pyralis). This oxidation is accompanied by emission 
of light which can be measured in a luminometer at a wavelength of 560 nm. Under 
substrate excess conditions, the emission of light is directly proportional to the 
amount of luciferase present and thus can be used to determine the translation 
efficiency of a RNA reporter construct coding for the firefly luciferase (Fluc). 
For this assay 80 - 90 % confluent HuH-7 cells grown in a 6-well plate were 
transfected (4.1.1.5) with a RNA reporter construct under varying conditions.  Three 
to nine hours post transfection the transfection medium was discarded and the cells 
were washed twice with approximately 1 ml of PBS. After washing the cells were 
lysed in the plate with 500 µl of Passive Lysis Buffer (PLB, Promega) at room 
temperature for 15 minutes under constant shaking. The lysates were transferred into 
a 2.0 ml reaction tube and centrifuged at 10000 rcf and 4 °C for 10 minutes to pellet 
the cell debris. At this point the samples may be stored for several days at -20 °C, or 
for prolonged storage periods -80 °C are advised. When thawing a sample it might be 
necessary to pellet the debris anew.  
For the luciferase assay 30 µl of the lysate were used. During the procedure which 
100 µl of the PJK Beetle Juice luciferase substrate were added. The measurement 
was carried out for 20 seconds in duplicates. To assess the unspecific background of 
the measurement either PLB alone or cell lysate of mock transfected cells was used 
as a blank.  
The PJK Firefly Assay Beetle Juice substrate was prepared according to the 
manufacturer’s specifications. 
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4.2 Materials  
 
4.2.1 Bacteria 
Strain  Company  Genotype 
E. coli HB101 Promega F–, thi-1, hsdS20 (rB–, mB–), supE44, recA13, ara-14, leuB6, 
proA2, lacY1, galK2, rpsL20 (strr), xyl-5, mtl-1 
E. coli XL1-Blue Stratagene recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)] 
 
4.2.2 Cell lines 
Cell line Source Origin 
HeLa 
 
Bartenschlager laboratory, Heidelberg, 
Germany 
Human cervix carcinoma 
HuH-7 
 
European collection of cell cultures 
(ECACC), Salisbury, UK 
Human hepatocellular 
carcinoma 
 
4.2.3 Kits 
Kit Company  Purpose 
SuperSignal West Femto Chemiluminescent 
Substrate 
Pierce Western Blot substrate  
Firefly Assay Beetle-Juice PJK luciferase substrate 
Illustra GFX PCR DNA and Gel Band 
Purification Kit 
GE healthcare PCR clean up, band purification 
NucleoBond PC100 Kit Macherey-Nagel Plasmid preparation, Maxi scale 
RNeasy Mini Kit Qiagen RNA clean up 
Wizard Plus SV Minipreps DNA purification 
System 
Promega Plasmid preparation, Mini scale 
 
4.2.4 Chemicals and radiochemicals 
Chemical  Company  
10 x 0.5 % trypsin EDTA  Life Technologies GmbH, Darmstadt, Germany 
Acetic Acid  Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Agarose  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Ammonium Persulfate Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Bromophenol blue  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Chloroform Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
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Chemical  Company  
Desoxyribonucleotidetriphosphates (dNTPs) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Dimethyl Sulfoxide (DMSO) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Di-sodium phosphate (Na2HPO4 – 7H2O) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Dulbacco’s modified Eagle’s medium (DMEM) Life Technologies GmbH, Darmstadt, Germany 
Easy tide α-32P-UTP PerkinElmer, Waltham, USA 
Ethyendiamintetraacetic acid (EDTA) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Ethanol (ACS reagent, > 99.5 %) Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Ethanol (denatured, 99%)  
Ethidiumbromide Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
FBS gold PAA Laboratories GmbH, Pasching, Austria  
Filter Tips (10 µl, 200 µl, 1250 µl)  Sarstedt, Nümbrecht, Germany 
Formamide Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Glycerol  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Glycine  Carl Roth GmbH & Co.KG, Karlsruhe, Germany  
Glycoblue Life Technologies GmbH, Darmstadt, Germany 
Isoamylalcohol Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Lipofectamine 2000  Life Technologies GmbH, Darmstadt, Germany 
Magnesium chloride (MgCl2) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Methanol  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Nonidet P-40, Biochemica [Ersatzprodukt] (NP-
40) 
AppliChem GmbH, Darmstadt, Germany  
Pefablock Roche GmbH, Mannheim, Germany 
Penicillin/Streptomycin 100 x (Pen/Strep) Life Technologies GmbH, Darmstadt, Germany 
Potassium chloride (KCl) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Potassium phosphate (KH2PO4) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Proteinase K [20 mg/ml] NEB, Ipswich, USA 
Reaction Tubes (2 ml, Safe Lock)  Sarstedt, Nümbrecht, Germany 
Ribonucleotidetriphosphates (rNTPs) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Roti Phenol   Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Rotiphorese Gel 40 (19:1) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Skimmed milk powder EDEKA Krenschker, Gießen, Germany  
Sodium acetate Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Sodium chloride (NaCl)  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Sodium Dodecyl Dulfate  (SDS) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Sodium fluoride (NaF) Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
TEMED (N,N,N',N'-Tetramethylethylendiamin) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
TriFast reagent  Peqlab Biotechnologie GmbH, Erlangen Germany  
Tris base  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Tween20 Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Urea Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
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Chemical  Company  
Xylenecyanol blue  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
β-Mercaptoethanol  Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
LB medium  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
 
4.2.5 Enzymes 
Enzyme  Company 
DpnI Fermentas 
One Taq Polymerase NEB 
Pfuturbo high fidelity DNA polymerase Stratagene 
Proteinase K NEB 
Sp6-RNA Polymerase Fermentas 
T7-RNA Polymerase Fermentas 
Various restriction enzymes  Fermentas or NEB 
 
4.2.6 Consumables 
Consumable  Company  
9 cm tissue culture dish  Sarstedt, Nümbrecht, Germany 
Autoclavable Waste Bags Sarstedt, Nümbrecht, Germany 
Chromatography Paper 3MM Chr (Whatman 
Paper) 
VWR, Darmstadt, Germany 
Filter Tips (10 µl, 20 µl, 200 µl, 1250 µl)  Sarstedt, Nümbrecht, Germany 
Pipette Tips (10 µl, 200 µl, 1000 µl)  Sarstedt, Nümbrecht, Germany 
PVDF Membrane Immobilon-P, 0.45 µm Milipore, Billerica, USA 
Reaction Tubes (15 ml, 50 ml)  Sarstedt, Nümbrecht, Germany 
Reaction Tubes (2.0 ml safe lock)  Sarstedt, Nümbrecht, Germany 
Sterile Serological Pipettes (5 ml, 10 ml, 25 ml) Greiner, Frickenhausen, Germany 
Tissue Culture Flasks (25 cm2, 75 cm2, 175 cm2) Sarstedt, Nümbrecht, Germany 
Tissue culture plates (24-wells, 6-wells) Sarstedt, Nümbrecht, Germany 
Luminometer tubes 5ml, 75 x 12 mm, PS Sarstedt, Nümbrecht, Germany 
Gene Pulser / Micro Pulser electroporation 
cuvettes 
Biorad, München, Germany 
 
 
 
4.2.7 DNA Primer 
Name  Sequence 
3’-UTR-only for 5’-CGTCAGAAGCTAGCGATTTAGGTG-3’ 
HCMV-4986 for 5’-CCAATAGGCCGAAATCGGCAAAATCCC-3’ 
HCV 3X rev 5’-ACATGATCTGCAGAGAGGCCAG-3’ 
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Name  Sequence 
HCV-FL 334-363 
rev 
5’-GAGGTTTAGGATTCGTGCTCATGGTGCACG-3’ 
HCV-FL 380-406 
rev 
5’-GGCGTCTTCCATGGTTTTTCTTTGAGG-3’ 
HCV-FL m1m2 for 5’-CGACTCACTATAGGTGGCCCCGATTGGGGGCGAGCGCGGCTTCTAGAT 
GTACAG -3’ 
HCV-FL m1m2 rev 
 
5’-CTGTACATCTAGAAGCCGCGCTCGCCCCCAATCGGGGCCACCTATAGT 
GAGTCG -3’ 
miR122 site2-
10nts-stem loop II 
fwd 
5’-CATAGATCACTCCTCTCGAGGTGCCTGTGAGGAACTAC-3’ 
 
miR122 site2-
10nts-stem loop II 
rev 
5’-GTAGTTCCTCACAGGCACCTCGAGAGGAGTGATCTATG-3’ 
miR122 site2-
20nts-stem loop II 
fwd 
5’-CCATAGATCACTCCGACTGATCTCGAGGTGGACTCCTGTGAGGAAC-3’ 
 
miR122 site2-
20nts-stem loop II 
rev 
5’-GTTCCTCACAGGAGTCCACCTCGAGATCAGTCGGAGTGATCTATGG-3’ 
miR122 site2-5nts-
stem loop II fwd 
5’-CCACCATAGATCACTCCTCGAGCCTGTGAGGAACTACTGTC-3’ 
miR122 site2-5nts-
stem loop II rev 
5’-ACAGTAGTTCCTCACAGGCTCGAGGAGTGATCTATGGTGG-3’  
NS5Bloop-
3’UTRfwd 
5’-GCAGGCTTAATACGACTCACTATAGCTCCTCCCCAACCGATGAAGGTT 
GGGGTAAACACTCCGGCC-3’ 
NS5Bloop-
3’UTRrev 
5’-ACATGATCTGCAGAGAGGCCAGTATCAGC-3’ 
RT-HCV pos. 233 
– 253 
5’-CTAGCAGTCTCGCGGGGGCAC-3’ 
RT-HCV pos. 9 – 
29 
5’-CGATTGGGGGCGACACTCCAC-3’ 
 
4.2.8 RNA Oligonucleotides 
microRNA Sequence 
miR-122 mat 5’-℗UGGAGUGUGACAAUGGUGUUUG-3’ 
miR-122* 5’-℗AACGCCAUUAUCACACUAAAUA-3’ 
miR-124 mat 5’-℗UGGAGUGUGACAAUGGUGUUUGUC-3’ 
miR-124* 5’-℗GCAACGCCAUUAUCACACUAAAUA-3’ 
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4.2.9 Plasmids 
Plasmid (also see appendix) Producer 
3-UTRonly Niepmann laboratory 
pHCV - FL  Niepmann laboratory 
pHCV - SIN Niepmann laboratory 
pHCV - FL miR-122 site2-5nts-stemloop II Dominik Conrad, Niepmann laboratory 
pHCV - FL miR-122 site2-10nts-stemloop II Dominik Conrad, Niepmann laboratory 
pHCV - FL miR-122 site2-20nts-stemloop II  (later 
pHCV - FL stem) 
Dominik Conrad, Niepmann laboratory 
 
4.2.10 Antibodies and magnetic beads 
Antibody / Magnetic Beads Company 
 AffiniPure goat-anti-Rat, LightChain*Specific Jackson ImmunoResearch, Newmarket, UK 
goat-anti-PTBP1 Abcam, Cambridge, UK 
Protein A magnetic beads  NEB, Ipswich, USA 
Protein G magnetic beads  NEB, Ipswich, USA 
rabit-anti-eIF3a Abcam, Cambridge, UK  
rat-anti-Ago1, clone 4B8 Sigma Aldrich, St. Louis, USA 
rat-anti-Ago2, clone 11A9 Sigma Aldrich, St. Louis, USA 
 
4.2.11 Laboratory Equipment 
Device Company 
B15 petri dish incubator  Thermo Scientific GmbH, Dreieich, Germany 
BioPhotometer Eppendorf, Wesseling-Berzdorf, Germany  
CB series CO2 Incubator Binder GmbH, Tuttlingen, Germany 
Centrifuge 5417R Eppendorf, Wesseling-Berzdorf, Germany 
Cronex Lightning Plus X-ray cassette  DuPont, Wilmington, USA 
Destamat, bi-destiller Heraeus, Hanau, Germany 
Digital-pH-Meter 644 Knick Elektronische Messgeräte GmbH & Co. 
KG, Berlin, Germany 
Duomax 1030 shaker  Heidolph, Schwabach, Germany 
Easyject Prima electroporator  EquiBio, Willstätt, Germany 
ED240 hot-air cabinet Binder GmbH, Tuttlingen, Germany 
EPS 5007400 electrophoresis power supply  Pharmacia Fine Chemicals, Uppsala, Sweden 
EPS 601 electrophoresis power supply  Amersham Bioscience, Glattbrugg, Switzerland 
FastBlot B44 semidry blotting chamber Biometra GmbH, Göttingen, Germany 
GelDoc XR gel documentation system  BioRad, München, Germany 
HA 2448 BS LaminAir lamina flow Heraeus, Hanau, Germany 
Heat-stir US152 magnetic stirrer  Stuart, Stone, UK 
Isopropanol tank  Qualilab, Olivet, France 
Julabo 7A water bath  Julabo, Seelbach, Germany 
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Device Company 
Julabo U3 water bath Julabo, Seelbach, Germany 
Labquake Rotator  Thermo Scientific GmbH, Dreieich, Germany 
LB 124 Geiger counter Berthold Technologies GmbH & Co.KG, Bad 
Wildbad, Germany 
Leica DM IL invers microscope Leica Microsystems, Wetzlar, Germany 
Lumat LB 9501 luminometer Berthold Technologies GmbH & Co.KG, Bad 
Wildbad, Germany 
MagnaRack magnetic separation rack  Life Technologies GmbH, Darmstadt, Germany  
MBT 250 heating block  Kleinfeld Labortechnik GmbH, Gehrden, Germany 
Micropipettors (2 µl-1000 µl) Gilson, Middleton, USA 
Model 583 Gel Dryer Biorad, München, Germany 
Multifuge 3L-R  Heraeus, Hanau, Germany 
Pipetboy comfort pipettor Integra Biosciences GmbH, Fernwald, Germany  
Polystar 100GE sealer Rische + Herfurth GmbH, Hamburg, Germany  
Severin 700 microwave Severin, Sundern, Germany 
Tecan infinite M200 multimode reader Tecan Deutschland GmbH, Crailsheim, Germany 
Thermicon T laboratory-type annealing furnace Heraeus, Hanau, Germany 
TProfessional PCR cycler Biometra GmbH, Göttingen, Germany 
V150 autoclave Systec, Wettenberg, Germany 
Vortex Genie 2 Scientific Industries, New York, USA 
 
4.2.12 Buffers 
 
4.2.12.1 Tissue Culture Buffers  
10 x PBS  80 g   NaCl 
  2 g  KCl 
  26.8 g  Na2HPO4 – 7H2O 
  2.4 g  KH2PO4 
  @ 800 ml H2O 
adjust pH 7.4 with HCl; adjust volume to 1 l 
with H2O for 1 x PBS dilute 1:10 with de-
ionized H2O; sterilize by autoclaving 
 
0.5 % Trypsin EDTA   dilute 10 x 0.5 % Trypsin EDTA 1:10 
   in 1 x PBS 
 
DMEM + 10 % FBS + 1% Pen/Strep (DMEM 10 %)  add 50 ml FBS gold and  
  5 ml Pen/Strep to 500 ml DMEM 
 
DMEM + 20 % FBS + 10 % DMSO (cryomedium)  add 10 ml FBS gold and  
  5ml DMSO @ 50ml DMEM 
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4.2.12.2 Gel Buffers  
10 x TBE (Tris-borate)  108 g    Tris 
  55 g   Boric Acid 
  40 ml   0.5 M EDTA (pH. 8.0) 
  @ 1 l   ddH2O 
 
50 x TAE (Tris-acetate)  242 g   Tris 
  100 ml   0.5 M EDTA (pH 8.0) 
  57.1 ml  Acetic Acid 
  @ 1 l   ddH2O 
 
4.2.12.3 Co-IP Buffers 
RNA Sample Buffer  80 %   Formamide  
  10 %   Gycerol  
  50 mM  EDTA pH 7.5 
  few grains bromphenolblue and  
  xylenecyanole 
  @ 20 ml  ddH2O 
 
Proteinase K Buffer  200 mM  Tris-HCl pH 7.5 
  300 mM NaCl 
  25 mM   EDTA pH 7.5 
  2 %   SDS 
  @ 50 ml  ddH2O 
 
Co-IP Lysis Buffer  25 mM   Tris-HCl pH 7.5 
  150 mM  KCl 
  2 mM  EDTA pH 7.5 
  0.5 mM  DTT 
  0.5 %   NP-40 
  @ 250 ml  ddH2O 
 
Co-IP-Wash Buffer  50 mM   Tris-HCl pH 7.5 
  0.3 M  NaCl 
  5 mM  MgCl2 
  0.05 %   NP-40 
  @ 500 ml  ddH2O 
 
Fixer solution   7.5 %   Acetic Acid 
  5 %   Ethanol  
  @ 1 l   de-ionized H2O 
 
Chloroform/Isoamylalcohol  24 ml   Chloroform  
       1 ml   Isoamylalcohol 
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4.2.12.4 IP Buffers 
IP-Lysis buffer  20 mM   Tris-HCl, pH 7.5  
150 mM   NaCl 
0.5 %  Nonidet P-40 
2 mM   EDTA 
0.5 mM   DTT 
1 mM   NaF 
1 mM  Pefablock 
@ 250 ml  ddH2O 
 
IP-Wash Buffer  50 mM   Tris-HCl pH 7.5 
  0.3 M  NaCl 
  5 mM  MgCl2 
  0.05 %   NP-40 
  @ 500 ml  ddH2O 
 
4.2.12.5 SDS-PAGE Buffers 
Acrylamide 30 % Dilute 150 ml Rotiphorese Gel 40 (19:1) with 
H2O to a final volume of 200 ml  
 
 
1.5 M Tris pH 8.8 (resolving gel buffer) 90.75 g   Tris  
 @400 ml   H2O 
 adjust pH to 8,8 with HCl; adjust  
 volume to 500 ml 
 
1.5 M Tris pH 6.8 (stacking gel buffer) 90.75 g   Tris  
 @400 ml   H2O 
 adjust pH to 6,8 with HCl;  
 adjust volume to 500 ml 
 
10 % SDS (w/v) 5 g   Sodium Dodecyl Sulfate  
 @ 50 ml   H2O 
 
10 % APS 0.1 g   Ammonium Persulfate  
 @ 10 ml   H2O 
 
 
10 x SDS Running Buffer 10 g  SDS 
 30 g   Tris 
 144 g   Glycine 
@ 1 l   de-inonized H2O,  
for 1 x SDS Running Buffer dilute 1:10  
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SDS Sample Buffer 20 %   Glycerol  
 20 %   β-Mercaptoethanol 
 60 %   10 % SDS 
 125 mM   Tris  
 few grains of Bromephenole blue  
 @ 25 ml   ddH2O 
4.2.12.6 Western Blot Buffer 
 
Cathode Buffer 3 g   Tris 
 @ 800 ml  H2O 
 adjust pH to 9.4 with HCl,  
 add 100 ml Methanol, adjust volume to 1 l  
 
Anode Buffer I  36.3 g   Tris 
 @ 800 ml  H2O 
 adjust pH to 10.4 with HCl, 
 add 100 ml Methanol, adjust volume to 1 l  
 
Anode Buffer II 3 g   Tris 
 @ 800 ml  H2O 
 adjust pH to 10.4 with HCl, 
 add 100 ml Methanol, adjust volume to 1 l  
 
10 x TBS  60.5 g  Tris 
 87.6 g   NaCl 
 @ 800 ml  H2O 
 adjust pH to 7.5 with HCl,  
adjust volume to 1 l; for 1 x TBS dilute 1:10 de-
ionized H2O 
 
TBS + 0.25 % Tween20 (TBST) add 2.5 ml Tween20 to 1 l of 1 x TBS 
 
TBST + 10 % milk powder (blocking buffer) add 10 g of skimmed milk powder to 100 ml 
TBST 
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5 Glossary 
 
5.1 Abbreviations 
µ micro (10-6) 
Ago Protein of the argonaute family  
AmpR Ampicilline resistance  
ApoE Apolipoprotein E 
Arg Arginine 
ATP Adenosine triphosphate 
ATX2 Ataxin 2 
bp Base pairs 
BSC Bio safety cabinet  
CD81 Cluster of Differenciation 81  
CLDN1 Claudin-1 
CSFV Classical swine fever virus 
ddH2O Double distilled water 
DDX DEAD-box helicase  
DMEM Dulbecco’s modified Eagle’s medium 
DNA Desoxyribonucleic acid 
DNase Desoxyribonuleic acid endonuclease 
dNTP Desoxy ribonucleic acid tri phosphate 
E. coli Escherischia coli 
ECACC European collection of cell cultures 
eIF Eukaryotic (translation)Initiation Factor  
ER Endoplasmic reticulum 
et al.  et alii (and others) 
EtBr ethidium bromide 
FBS Fetal bovine serum  
FLuc Firefly luciferase 
FMDV Foot and mouth disease 
GAG glycosaminoglycan 
GBV-B GB-virus B 
h hour 
HCC hepatocellular carcinoma 
HCl Hydrochloric acid 
HCV Hepatitis C virus 
His Histidine 
hnRNP heterogenous ribonucleoproteins 
HSC Heat shock cognate protein  
IFITM1 Interferone induced transmembrane protein 1 
IFN Interferone 
Ig immune globulin 
IMP-1 insulin-like growth factor-II mRNA-binding protein 
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IP immunoprezipitation 
IRES internal Ribosome entry site  
ITAF IRES trans-acting factor 
kb kilo bases 
kDa kilo Dalton 
KO Knock out 
l liter 
LB Lysogeny Broth 
LD lipid droplet 
LSm like SM protein 
M Molar mol/l 
m milli (10-3) 
mat mature 
min minute 
miR microRNA 
miR* Passanger strand of miR duplexes 
miRNP complex microRNA-protein complex 
mRNA messanger RNA 
NEB New England Biolabs 
NP-40 Nonidet P-40  
NS Nonstructural protein 
NSAP1 NS1-associated protein 1 
Nt(s) Nucleotide(s) 
OCLN Occludin 
OD optical density 
ORF open reading frame 
P phosphate 
PABP poly(A) binding protein 
PACT Protein kinase R-associated activator 
PAGE Polyacrylamide gel electrophoresis  
P-body processing body 
PBS phosphate buffered saline 
PCBP1 Poly(rC)-binding protein 1 
PCR polymerase chain reaction  
PEG polyethylene glycol  
Pen/Strep Penicillin/Streptomycin solution  
pH Decimal cologarithm of hydrogen concentration 
PLB Passive lysis buffer 
pre precursor 
pri primary  
PTB Polypyrimidine tract-binding protein 
PVDF Polyvinylidene fluoride 
Py poly-pyrimidine tract 
rcf relative centrifugal force 
RISC RNA induces silencing complex 
RLuc Renilla luciferase 
RNA  ribonucleic acid 
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RNase RNA endonuclease 
rNTP ribonucleic acid tri-phosphate 
rpm rounds per minute 
RRM RNA recognition motif 
RT-PCR reverse transcriptase-PCR 
rUTP Uridine triphosphate 
s second 
SIN short and in frame  
SL Stem loop 
SR-BI Scavenger receptor BI 
t1/2 half-life 
TAE Tris-acetate-EDTA buffer 
Taq thermo aquaticus  
TBE Tris-borate-EDTA buffer 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween20 
TGF-β Transforming growth factor-β 
TRBP HIV-1 TAR RNA-binding protein 
tRNA transfer RNA  
tRNAiMet Initiator tRNA 
U Unit 
UTR untranslated region  
UV Ultra violet  
V Volt 
v/v Volume/Volume 
VR Variable region 
w/v Weight/volume 
WHO World health organization 
wt Wild type 
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6 Appendix 
6.1 Plasmid maps  
6.1.1 pHCV-FL 
 
 
 
feature  description  start - stop [nt] 
T7  Promoter for T7 RNA polymerase 5393 - 5410 
HCV 5’-UTR Sequence of the HCV 5’-
untranslated region  
1 - 341 
Core l Fragment of the HCV Core coding 
sequence  
342 – 374 
Firefly luciferase  ORF for the firefly luciferase 375 - 2027 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
2028 – 2248 
AmpR Ampicillin resistance gene 4327 – 3467  
 
Description: Given are the relative positions of structural features present on the pHCV-FL 
expression plasmid. The T7 RNA polymerase promoter can be used to in vitro transcribe a 
HCV RNA reporter construct comprising the firefly luciferase ORF, flanked by the HCV 5’- 
and 3’-UTR. The Core linker is necessary for the proper folding of the HCV 5’-UTR after in 
vitro transcription. In opposite direction the location of the Ampicillin resistance gene is given, 
which is necessary for selection and amplification of the plasmid. The plasmid a ha total size 
of 5410 nts. 
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6.1.2 pHCV-FL miR-122 site 2-5nts-stem loop II 
 
 
 
feature  description  start - stop [nt] 
T7  Promoter for T7 RNA polymerase 5393 - 5410 
HCV 5’-UTR Sequence of the HCV 5’-
untranslated region  
1 - 351 
Insetion 5 nts insertion including a XbaI 
restriction site  
43 - 47 
Core l Fragment of the HCV Core coding 
sequence  
347 – 379 
Firefly luciferase  ORF for the firefly luciferase 380 - 2032 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
2033 – 2253 
AmpR Ampicillin resistance gene 4332 – 3473  
 
Description: Given are the relative positions of structural features present on the pHCV-FL 
miR-122 site 2-5nts-stem loop II expression plasmid. The T7 RNA polymerase promoter can 
be used to in vitro transcribe a HCV RNA reporter construct comprising the firefly luciferase 
ORF, flanked by the HCV 5’- and 3’-UTR. The 5’-UTR carries an insertion of 5 nts between 
miR-122 site 2 and stem loop II of the HCV IRES. The insertion was generated by Quick 
Change in vitro mutagenesis, using a XbaI restriction site to identify positive mutations. The 
Core linker is necessary for the proper folding of the HCV 5’-UTR after in vitro transcription. 
In opposite direction the location of the Ampicillin resistance gene is given, which is 
necessary for selection and amplification of the plasmid. The plasmid has a total size of 5415 
nts. 
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6.1.3 pHCV-FL miR-122 site 2-10nts-stem loop II 
 
 
 
feature  description  start - stop [nt] 
T7  Promoter for T7 RNA polymerase 5393 - 5410 
HCV 5’-UTR Sequence of the HCV 5’-
untranslated region  
1 - 351 
Insetion 10 nts insertion including a XbaI 
restriction site  
43 - 52 
Core l Fragment of the HCV Core coding 
sequence  
342 – 374 
Firefly luciferase  ORF for the firefly luciferase 385 - 2037 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
2038 – 2258 
AmpR Ampicillin resistance gene 4337 – 3477  
 
Description: Given are the relative positions of structural features present on the pHCV-FL 
miR-122 site 2-10nts-stem loop II expression plasmid. The T7 RNA polymerase promoter 
can be used to in vitro transcribe a HCV RNA reporter construct comprising the firefly 
luciferase ORF, flanked by the HCV 5’- and 3’-UTR. The 5’-UTR carries an insertion of 10 nts 
between miR-122 site 2 and stem loop II of the HCV IRES. The insertion was generated by 
Quick Change in vitro mutagenesis, using a XbaI restriction site to identify positive mutations. 
The Core linker is necessary for the proper folding of the HCV 5’-UTR after in vitro 
transcription. In opposite direction the location of the Ampicillin resistance gene is given, 
which is necessary for selection and amplification of the plasmid. The plasmid has a total 
size of 5420 nts. 
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6.1.4 pHCV-FL stem 
 
 
 
feature  description  start - stop [nt] 
T7  Promoter for T7 RNA polymerase 5393 - 5410 
HCV 5’-UTR Sequence of the HCV 5’-
untranslated region  
1 - 361 
Insetion 20nts insertion including a XbaI 
restriction site  
43 - 62 
Core l Fragment of the HCV Core coding 
sequence  
362 – 394 
Firefly luciferase  ORF for the firefly luciferase 395 - 2047 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
2048 – 2268 
AmpR Ampicillin resistance gene 4347 – 3487  
 
Description: Given are the relative positions of structural features present on the pHCV-FL 
stem expression plasmid. The T7 RNA polymerase promoter can be used to in vitro 
transcribe a HCV RNA reporter construct comprising the firefly luciferase ORF, flanked by 
the HCV 5’- and 3’-UTR. The 5’-UTR carries an insertion of 20 nts between miR-122 site 2 
and stem loop II of the HCV IRES. The insertion was generated by Quick Change in vitro 
mutagenesis, using a XbaI restriction site to identify positive mutations. When transcribed the 
insertion forms an artificial stem loop in the HCV 5’-UTR masking the two miR-122 sites, 
redering them unable to hybridize to miR-122. The Core linker is necessary for the proper 
folding of the HCV 5’-UTR after in vitro transcription. In opposite direction the location of the 
Ampicillin resistance gene is given, which is necessary for selection and amplification of the 
plasmid. The plasmid has a total size of 5430 nts. 
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6.1.5 pHCV-SIN 
 
 
 
feature  description  start - stop [nt] 
T7  Promoter for T7 RNA polymerase 3219 - 3235 
HCV 5’-UTR Sequence of the HCV 5’-
untranslated region  
1 - 341 
Core  Fragment of the HCV Core coding 
sequence  
342 -+ 402 
Linker Part of the firefly luciferase ORF 403 - 437 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
438 - 658 
AmpR Ampicillin resistance gene 2737 – 1877  
 
Description: Given are the relative positions of structural features present on the pHCV-SIN 
expression plasmid. The T7 RNA polymerase promoter can be used to in vitro transcribe a 
HCV RNA reporter construct comprising a small linker comprised of parts of the core protein 
and firefly luciferase coding sequence, flanked by the HCV 5’- and 3’-UTR. In opposite 
direction the location of the Ampicillin resistance gene is marked, which is necessary for 
selection and amplification of the plasmid. The plasmid has a total size of 3235 nts. 
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6.1.6 3’-UTR only 
 
 
 
feature  description  start - stop [nt] 
Sp6 Promoter for Sp6 RNA 
polymerase 
1 - 21 
Linker  Small linker sequence derived 
from the firefly luciferase ORF 
22 - 62 
HCV 3’-UTR Sequence of the HCV 3’-
untranslated region 
63 - 283 
AmpR Ampicillin resistance gene 2370 - 1510  
 
Description: Given are the relative positions of structural features present on the 3’-UTR 
only expression plasmid. The Sp6 RNA polymerase promoter can be used to in vitro 
transcribe a HCV RNA reporter construct comprising a small liker sequence derived from the 
firefly luciferase ORF, flanked downstream by the HCV 3’-UTR. The linker is necessary for 
the proper folding of the HCV 3’-UTR after in vitro transcription. In opposite direction the 
location of the Ampicillin resistance gene is given, which is necessary for selection and 
amplification of the plasmid. The plasmid has a total size of 3571 nts. 
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